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ESTIMATION OF FIRST TRIMESTER SERUM URIC ACID 
LEVELS AS A PREDICTOR OF PREECLAMPSIA AMONG 
SINGLETON PREGNANT PATIENTS ATTENDED OVER A 
ONE YEAR PERIOD AT A TERTIARY CARE INSTITUTION. 
- A PROSPECTIVE COHORT STUDY 
 
ABSTRACT: 
It is a prospective study conducted  on 197 antenatal women with 
singleton pregnancy attended antenatal op over a one year period at KMCH. 
Uric acid was measured from maternal plasma samples that were collected at 
a mean gestational age of 11.2 weeks. High first trimester serum uric acid was 
associated with increased risk of preeclampsia but not gestational 
hypertension. There was no linear association between first trimester uric acid 
and small for gestational age. There was no linear association between first 
trimester uric acid and preterm delivery. 
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Introduction 
5 to 10% of all pregnancies are complicated by hypertensive 
disorders.Preeclampsia isa multisystem disorder associated with significant fetal 
and maternal morbidity and mortality.Incidence of preeclampsia ranges from 5-
15% and in Indiaincidence is 8-10%. 
Preeclampsiaassociated with hypertension,proteinuria and edema which 
is evidentafter 20 weeksgestation andresolvesafter delivery.So understanding of 
pathophysiologyis very important tosearchfor the markersthatpredictthe 
occurrence of preeclampsia.According to many studies preeclampsia is 
associated with abnormal placentation and endothelial dysfunction. 
Predictive tests will enable to discriminatehigh risk and low risk 
patientstodevelop preeclampsia.Itwill also identify the patients who may 
developclinically significant diseaseso it may help to identifythose patientsfor 
targeted prophylaxis once a therapy is identified. 
Serum uric acid in first trimester can be a good predictor of development 
of preeclampsia and its estimation is a simple biochemical screening test to 
predict the development of preeclampsia. 
Hyperuricemiais associated with manycomplications such as 
hypertension,metabolic syndrome,chronic kidney diseaseand diabetesin non-
pregnant adults.They are high risk factors for the development of 
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Preeclampsia.Hyperuricemia frequently occurs before the development of 
hypertension and proteinuria in pregnancy. 
Serum uric acid isnotonly biomarkerfor the preeclampsia,it can also play 
an important role in the pathogenesis of preeclampsia.So it was found to have a 
pathogenic role in the development of preeclampsia.Serum uric acidis a simple 
screening test in the first trimester to predict high risk patients who are prone to 
develop preeclampsia. 
Preeclampsia is responsible for 16% of maternal mortality even in 
developed countries according to World Health Organization (WHO).We can 
prevent 50% of these preeclampsia related deaths. 
Thus early identification of high risk pregnancies may enhance 
development of new strategies for antenatal monitoring to detect the disease at 
earliest.So we can intervene appropriately to improve maternal and perinatal 
outcome. 
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Review of Literature 
Hypertension is the second most common cause of maternal 
mortality.Preeclampsia is a multisystem disorder affecting every organ in the 
body.According to International Society for the Study of Hypertension in 
Pregnancy (ISSHP), Hypertension is defined as systolic blood pressure of 
>140mmHg or diastolic blood pressure of 90mmHg. 
A rise in the systolic blood pressure of 30 mmHg or a rise in the diastolic 
blood pressure of 15mmHg, at least 4 hours apart or a single diastolic blood 
pressure >110mmHg is also considered as hypertension. 
Blood pressure gradually decreases to a nadir between 14 and 24 weeks 
innormal pregnancy and increased to pre-pregnancy levels in third trimester and 
the fall in blood pressure is due to reduced vascular tone which leads to 
peripheral vasodilation. 
Classification of hypertension disorders complicating pregnancy adopted by 
the ISSHP [international society for the study of hypertension in pregnancy] are 
as follows 
• Gestational hypertension  
• Preeclampsia 
• Chronic hypertension 
 Essential 
 Secondary 
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• Preeclampsia superimposed on chronic hypertension. 
 
Gestational Hypertension 
New onset hypertension without proteinuria developing after 20 weeks of 
gestation in a previously normotensive non-proteinuric women and the blood 
pressure returns to normal with in a 12 weeks postpartum. 
 
Preeclampsia 
Hypertension associated with proteinuria >0.1g/L or more in at least 2 
random urine specimens collected at least 6hours apart or >0.3g/dl in a 24 hour 
collection in a previously normotensive non-proteinuric women developing 
after 20 weeks of gestation and returns to normal by 12 weeks postpartum. 
 
Chronic Hypertension 
Defined as hypertension developing before 20 weeks of gestation without 
an apparent underlying cause or secondary to renal,endocrine or vascular 
disorders. 
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Chronic Hypertension Superimposed Preeclampsia 
New onset proteinuria in a woman with chronic hypertension after 20 
weeks of gestation. 
Incidence 
Incidence of hypertensive disorders of pregnancy is about 15-20% of all 
pregnancies. 
Preeclampsia-3 %-8% 
 
Risk Factors 
• Nulliparity/primipaternity/teenage pregnancy 
• Genetic predisposition 
• Increased maternal age 
• Multifetal gestation 
• Hydatidform mole 
• Triploidy  
• Hydrops fetalis with large placenta. 
• Preeclampsia in a previous pregnancy 
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• Chronic hypertension 
• Renal disease 
• Connective tissue disorders 
• Obesity 
• Insulin resistance 
• Diabetes 
• H/o thrombophilia 
• Antiphospholipid syndrome  
• Hyperhomocystinemia 
• Sickle cell disease, sickle cell trait 
 
Etiopathogenesis 
Preeclampsia is a disease of the placenta and the fetus is not required for 
the development of preeclampsia. 
The following mechanisms contribute to pathogenesis of placenta 
• Shallow,endovascular cytotrophoblast invasion in the spiral arteries. 
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• Endothelial cell dysfunction.  
• Immunological maladaptation tolerance to maternal, paternal and fetal 
tissues. 
• Maternal maladaptation to cardiovascular or inflammatory changes of 
normal pregnancy 
• Genetic predisposition. 
• Hyperexaggerated inflammatory response. 
Preeclampsia is a two stage disorder associated with abnormal placentation 
and second stage of clinical disease maternal hypertensive syndrome. 
 
Abnormal Placentation 
The embryo derived cytotrophoblasts invade the maternal uterine wall 
during normal placentation and the cytotrophoblasts are found in the smooth 
muscle and endothelial layers of maternal decidual arteries after invasion. 
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Figure 1 indicates normal and abnormal placentation respectively 
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The remodelling of maternal vessels into the highcapacitance and low 
resistance vessels which provides access for maternal oxygen and nutrients for 
the developing fetus and this process is demolishedin preeclampsia. 
There is incomplete invasion of the trophoblasts which results in narrow 
bore constricted, high resistance vessels.The shallow invasion of 
cytotrophoblasts may result in the failure of cytotrophoblasts to adopt an 
endothelial adhesion phenotype. 
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Figure 2 indicates normal and abnormal placentation respectively 
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Hypoxia may also contribute to abnormal placental development because 
under hypoxia there is failure of invasion of trophoblasts in vitro and the 
hypoxia leads to release of placental debris into the maternal circulation inciting 
a systemic inflammatory response. So there is high risk of preeclampsia in 
women who are living at high altitude. 
Endothelial cell dysfunction caused by imbalance between prostacyclin 
and thromboxane.Recently circulating anti-angiogenic proteins have been 
implicated in the pathogenesis of placenta. 
Roberts and Taylor advanced the hypothesis that preeclampsia result 
from the release of circulating factors leading to widespread endothelial 
dysfunction.All markers of endothelial injury,fibronectin,factor 8 antigen and 
thrombomodulin have been reported to increase in patients with preeclampsia. 
sFlt-1 (soluble fms like tyrosine kinase)is an anti-angiogenic factor  is a 
potent inhibitor of VEGF and PIGF may play a causal role in the pathogenesis 
of preeclampsia and it is increased in placenta and blood of preeclampsia 
patients with onset before 37 weeks , severe preeclampsia patients,preeclampsia 
with delivery of small for gestational age. 
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Figure 3 indicates role of angiogenic and anti-angiogenic factors in normal and 
preeclamptic patients respectively. 
 
But sFlt-1 levels were increased only within 5 weeks before the onset of 
hypertension and proteinuria. 
Another anti-angiogenic protein sEng soluble endoglin combine with 
sFlt1 to induce the features of severe preeclampsia and it begins to rise after 
20weeks of gestation and rise more steeply after 33 weeks in women of 
preeclampsia patients. 
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The concentration of free PIGF is reduced in preeclampsia and PIGF 
concentration begins to decrease 9-11weeks before the onset of 
preeclampsia.Other angiogenic factors like VEGF lower in severe preeclampsia 
patients.Factors like sFlk-1 (SVEGFR-2) levels found to be lower in 
preeclampsia patients compared to other patients. 
 
Figure 4 indicates pathogenesis of preeclampsia 
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Immunologic maldysfuncion at maternal fetal interface may contribute to 
pathogenesis of preeclampsia and the pathologic examination of preeclamptic 
patients shows increased dendritic and macrophage infiltration and signs of 
chronic inflammation. 
Decidual natural killer cells involvedin trophoblastic invasion which 
promote angiogenesis may contribute to abnormal placental development in 
preeclampsia. 
Other mechanisms like increased angiotensin sensitivitydue to 
angiotensin receptor autoantibodies contribute to pathogenesis of 
preeclampsia.Alterationin placental enzymes like deficiency of 2-
methoxyestradiol involved in pathogenesis of preeclampsia. 
Heme oxygenase is a negative regulator of sFlt1 production elevated in 
smokers which reduces the risk of preeclampsia in smokers. 
 
Role of Uric Acid in the Pathogenesis of Preeclampsia 
Uric acid is an end product of metabolism of purine compounds and its 
daily synthesis is about 400mg and from dietary sources about 300mg. Normal 
uric acid pool in males is about 1200 mg and in females is about 600 mg. 
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75% of serum uric acid is excreted in urine and its remainder is degraded 
to allantoin in the gastrointestinal tract by the bacterial enzymes. 98-100% of 
uric acid is reabsorbed in proximal convoluted tubule and it is secreted into the 
distal proximal convoluted tubule and further it is absorbed in to the distal 
convoluted tubule. 
Net excretion of uric acid is 6-12%  and normal serum urate level in 
males ranges from 2.5-8mg/d  and  in females ranges from 1.9- 7.5mg/dl. 
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Figure 5 indicates synthesis of uric acid from purines 
 
Normally Serum uric level in healthy pregnancies decreases from an 
average of 4.2mg/dl pre-pregnancy to 3.1 +/- 1.1mg/dl in the first trimester and 
slowly increases during gestation to an average of 5.2 mg +/- 1.2mg/dl from 35 
weeks of gestation to term. 
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In pregnancy uric acid excretion is disproportionately larger than increase 
in filtered load , so net reabsorption of uric acid is reduced in normal pregnancy 
hence fall in serum uric level. 
The excretion of serum uric acid remains constant as thepregnancy 
advanceseven though there is gradual increase in filtered load. 
Uric acid contribute to pathogenesis of preeclampsia by following mechanisms 
Uric acid activates the inflammation in the trophoblast and IL-1 beta 
production which induces inflammation at the maternal fetal interface leading to 
placental dysfunction and preeclampsia. 
• Inhibit endothelial function 
• Induce oxidative stress 
• Increases systemic blood pressure 
• Induces insulin resistance 
• Uric acid also inhibits fetal angiogenesis. 
 
Placenta 
Characteristic pathophysiologic change is atherosis.Characterized by 
fibrinoid necrosis,macrophages and mononuclear cell infiltration. 
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Cardiovascular System 
Cardiac changes in preeclamptic patients are increased cardiac afterload 
and increased cardiac preload and hemoconcentration.Hemoconcentration is due 
to generalised vasoconstrictionthat follows endothelial activation and leakage of 
plasma into interstitial space. 
 
Hematology 
Thrombocytopenia is most common finding and less than one lakh 
platelet count indicates severe disease.Severe preeclampsia is characterized 
bymicroangiopathic haemolytic anaemia and associated with FACTOR 8 
consumption,increased levels of fibrinopeptides A and B,increased fibrin 
degradation products and decreased levels of antithrombin ,protein C and 
protein S. 
 
Kidney 
Glomerular endotheliosis is the characteristic pathophysiologic change in 
the kidney. Glomerular endotheliosis occlude the filtration barrier due to fibrin 
deposition, so glomerular filtration is mildly reduced. 
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Main pathological change is glomerular and tubular dysfunction and 
responsible for proteinuria, reduction in glomerular filtration rate and creatinine 
clearance. 
Acute renal failure rarely occurs which is caused by acute tubular 
necrosis. 
Serum uric acid is elevated which is due to enhanced tubular 
reabsorption.Placental ischemia also causes hyperuricemia due to increased 
trophoblast turnover and production of purines 
 
Liver 
Characteristic features are periportal haemorrhage in the periphery of the 
liver and increase in the liver enzymes SGOT and SGPT and clinical jaundice 
can occur.In severe preeclampsia serum transaminases are elevated. 
The small haemorrhages combine to form subcapsular hematoma which 
stretches glissons capsule responsible for epigastric pain which is a very serious 
sign in impending eclampsia. 
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Brain 
Cerebral vasospasm is the main pathologic finding in brain.Cortical and 
subcortical petechial hemorrhages are the principal lesions. 
In eclampsia cerebral haemorrhages, fibrinoid necrosis and thrombi can 
occur and secondary to endothelial dysfunction.Cerebral edema can also occur 
in eclampsia and cerebral haemorrhage which is a rare complication can occur 
in severe preeclampsia. 
Visual changes like scotoma, blurring of vision or diplopia will occur in 
severe preeclampia or eclampsia are due to edema of occipital lobe. 
Blindness arise from three potential areas 
1. Visual cortex of occipital lobe 
2. Lateral geniculate nuclei 
3. Retina 
Purscher retinopathyresulting from blindness caused by retinal ischemia and 
infarction.Cortical blindness can also occur due to occipital edema. 
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Eyes 
Commonest finding is localised retinal vasospasm and haemorrhages and 
papilloedema rarely seen in severe hypertension. 
 
Complications 
Preeclampsia is a multisystem disorder affecting every organ in the body. 
 
Maternal 
• Eclampsia 
• Cerebral haemorrhage 
• Cortical blindness 
• Pulmonary edema 
• Adult respiratory distress syndrome 
• HELLP syndrome 
• DIC and haemorrhage 
• Acute renal failure. 
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• Hepatic rupture 
• Abruptioplacenta and sudden postpartum collapse. 
• Stroke  
• Long term cardiovascular morbidity 
 
Fetal Complications 
• Preterm delivery  
• Fetal growth restriction  
• Intrauterine death 
• Long term cardiovascular morbidity associated with low birth weight 
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Predictors of Preeclampsia 
Many markers have been proposed as predictors for preeclampsia for early 
detection of high risk pregnancies to improve maternal and perinatal outcome. 
• Biological, biochemical,biophysical markers of placental perfusion 
• Markers of Vascular resistance 
• Markers of placental - endocrine dysfunction 
• Markers of oxidant stress 
• Markers of endothelial dysfunction 
• Markers of activated coagulation 
But no single test is economical and sensitive. 
1. Diastolic Blood Pressure 
Diastolic blood pressure prior to 20 weeks of gestation >85mmHg 
93-97% specificity is more predictor of preeclampsia. 
2. Mean Arterial Pressure 
Mean arterial pressure in the second trimester [18-26weeks] >90 
mmHg is more predictor of preeclampsia. 
Specificity 68% 
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3. Gants Roll Over Test [supine pressor test] 
The woman is turned from the left lateral to the supine position. If 
there is an increase in the diastolic blood pressure of 20mmHg or more, 
the test is considered positive 
4. Isometric Exercise Test[hand grip test] 
Increased systolic BP >15 mmHg 
Increased diastolic BP >20mmHg 
5. Angiotensin Sensitivity Test 
It is based upon fact that women who destined to develop 
preeclampsia develop refractoriness between 28-32 weeks of gestation 
If pressor response occurs with <8ng/kg/min of infused 
angiotensin,90% of the patients likely to develop preeclampsia.But this 
test is invasive. 
6. Uterine Artery Doppler 
Normallyin the non-pregnant state diastolic flow is decreased and 
notching of uterine arteries. In normal pregnancy diastolic notch 
disappears and flow increases due to trophoblastic invasion. 
In preeclampsia second wave of trophoblastic invasion has not 
occurred and there is persistent of diastolic notch in the uterine artery at 
20-22weeks of gestation which is predictive of 
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preeclampsia.Disappearance of the notch is more likely to predict that the 
pregnancy is normal. 
7. Pulse Wave Analysis 
Stiffness in the finger arterial pulse acts as apredictor. 
8. Raised Serum BETA HCG at 14-20 weeks of gestation 
Beta HCG is increased due to abnormal trophoblastic invasion. It is 
also increased due to placental dysmaturity. Increased production by 
hypoxic trophoblasts. 
9. Tests related to feto placental unit endocrine dysfunction 
• Alpha feto protein 
• Estriol levels 
• Inhibin levels 
• Pregnancy associated plasma proteins 
• Activin level 
• Placental protein 13 
• Corticotrophin releasing hormone 
Other markers are 
• Platelet count 
• Sflt-1fms like tyrosine kinase receptor  
• Endoglin 
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• Plasminogen activator inhibitor 
• Neurokinin bp selectin 
• Decreased levels of proangiogenic factors like vascular endothelial 
factor, placental growth factor,endothelial adhesion molecules 
10. Dyslipidemia is also predictor of preeclampsia 
Lipid markers are triglycerides,free fatty acids and   lipoproteins are 
predictors of preeclampsia. 
11. Serum Uric Acid 
Uric acid is also one of the predictor of preeclampsia.Uric acidis 
elevated due to abnormal renal function,placental ischemia 
andtrophoblast turn over and production of purines and increased activity 
of the enzyme xanthine oxidase/dehydrogenase. 
Hyperuricemia in pregnancy occurs before the onset of 
hypertension and proteinuria and found to have a pathogenic role in the 
development of preeclampsia. 
Uric acid is a product of purine degradation catalysed by the 
enzyme xanthine ehydrogenase/xanthine oxidase and along with 
production of uric acid free radical superoxide is produced and 
contributes to oxidative stress. 
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Humans do not possess the enzyme uricase so uric acid clearance 
depends upon renal excretion.Uric acid is a potent mediator of 
inflammation. 
 
Uric Acid in Pregnancy 
Uric acid concentration is higher in men and postmenopausal women 
because estrogen is uricosuric and its concentration in pregnancy fall initially 
due to high estrogen, expanded plasma volume and increased glomerular 
filtration rate. 
Endothelial cells which produce nitric oxide production reduced by uric 
acid,hence migratory and invasive phenotype of trophoblast is modified. 
In preeclampsia patients since uric acid is elevated prior to10th week 
gestation so indirectly contributes to inadequate trophoblast invasion and spiral 
arteriole remodelling. 
Uric acid found to damage the placental vasculature by stimulating the 
production of mediators of inflammation and inhibit fetal growth.Since uric acid 
reduces nitric oxide production which is a potent vasodilator there will be 
altered endothelial function which contributes to pathogenesis of placenta. 
The increasing concentration of circulating TNFalpha in preeclamptic 
patients positively correlated with serum uric concentrations. 
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Chronic hyperuriemia is associated with reduced release of endothelium 
progenitor cells which is reduced in preeclampsia. 
To conclude uric acid is converted to urate crystal which acts on placenta 
and maternal vasculature. 
 
Placenta 
• Inhibition of nitric oxide production 
• Decreased invasion of trophoblasts and remodelling 
• Endothelial cell dysfunction 
• Smooth muscle proliferation 
• Compromises placental perfusion 
• Oxidative stress and inflammation 
 
Maternal Vasculature 
• Smooth muscle cell proliferation 
• Endothelial cell dysfunction 
• Activates inflammation 
• Oxidative stress 
• Inhibition of endothelial nitric oxide production 
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Management of Preeclampsia 
Hypertension complicating pregnancy is managed according to severity, 
gestational age and associated preeclampsia.The main objective of treating 
preeclampsia is to prevent maternal and fetal morbidity and mortality. 
 
Management of Mild Preeclampsia 
Mild preeclampsia can be managed on outpatient basis with the help of 
day care units.Effective monitoring of mother and fetus is essential.Patient 
should visit hospitalat leastonce weekly after the diagnosis of preeclampsia. 
All parameters should be evaluated if they are normal patient can be 
managed on an outpatient basis.No role of diuretics in the management of 
preeclampsia except when preeclampsia associated with pulmonary edema. 
The use of antihypertensive drugs in mild preeclampsia remains 
questionable.The main objective of treatment with anti-hypertensive is to reduce 
the risk of severe hypertension,eclampsia and cerebrovascular haemorrhage. 
There is loss of cerebral auto-regulation and risk of cerebral haemorrhage 
once the mean arterial blood pressure reaches 150mmHg. 
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The first lines of drugs are 
• Labetalol 
• Nifedipine 
• Alpha-MethylDopa 
 
Maternal Monitoring  
• Daily urine albumin 
• Blood pressure daily 
• Daily weight 
• History of imminent symptoms 
• Lab tests like platelet count, liver and renal function tests,serum uric acid 
twice weekly 
• Coagulation profile 
 
Fetal Monitoring 
• Fetal kick count daily 
• NST and amniotic fluid index twice weekly 
• Ultrasound to assess gestational age and growth 
• Umbilical Artery Doppler. 
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The only definitive treatment for preeclampsia is delivery.Patients with mild 
preeclampsia can be induced at 38 weeks of gestation. 
Pregnancy should be terminated earlier if there is progression of mild to 
severe preeclampsiaor imminent eclampsia or eclampsia and for obstetric 
indications like IUGR.If pregnancy is terminated before 34 weeks 
corticosteroids are given for lung maturity and to prevent respiratory distress 
syndrome. 
Labour can be induced vaginally if there are no obstetric indications for 
caesarean section.If the cervix is unfavourable induce with dinoprostone gel 
vaginally and artificial rupture of membranes, oxytocin acceleration if the 
cervix is favourable.During labour continuous blood pressure monitoring, CTG 
monitoringand active management of third stage of labour is followed. 
 
Severe Preeclampsia 
Criteria for severe preeclampsia 
• Systolic blood pressure of >160mmHg or diastolic blood pressure of 
110mmHg on atleast two occasions 6 hours apart 
• 5g proteinuria or higher in a 24 hour urinary specimen 
• Oliguria 
• Pulmonary edema 
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• Visual disturbances 
• Epigastric pain 
• Thrombocytopenia 
• Elevated liver enzymes 
• Fetal growth restriction 
 
Since there is deterioration of maternal or fetal condition the only definitive 
treatment is delivery.Severe preeclampsia>34 weeks is terminated if there is 
worsening of biochemical parameters.Less than 24 weeks also best managed by 
termination whereas onset of severe preeclampsia<34 weeks but greater than 28 
weeks there is role of expectant management for the sake of the fetus. 
 
Management of severe preeclampsia 
• Admit to the labour ward. 
• Complete maternal and fetal evaluation within 24 hours. 
• Start anti-hypertensives if systolic BP>160 or diastolic BP >110 to 
prevent cerebral haemorrhage. 
• Use prophylactic magnesium sulphate regimenis used to prevent or 
reduce complications and rate of seizures. 
• Inject steroids tohelp speed the infant’s lung maturity. 
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• Terminate pregnancy immediately if there is deterioration of maternal or 
fetal condition or developing complications like eclampsia,pulmonary 
oedema, abruption placentae,disseminated intravascular coagulation 
(DIC),acute renal failure, HELLP syndrome,non-reassuring fetal status 
pregnancy is immediately terminated. 
 
Intrapartum Management 
• Close monitoring of blood pressure is necessary. IV labetolol can be used 
for high blood pressure.  
• Rapid fall in blood pressure is detrimental to both mother and fetus, so 
close monitoring is needed. 
• Continue to use magnesium sulphate to prevent convulsions. 
• Avoid fluid overload as preeclamptic patients are prone for pulmonary 
oedema.  
• Transfuse fresh frozen plasma or blood products if there is DIVC. 
• Indicate caesarean section if there is worsening of maternal condition, 
non-reassuring fetal pattern, failed induction or other associated obstetric 
indications. 
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Eclampsia 
• Eclampsia is defined as onset of generalised tonic clonic seizures in a 
preeclamptic patient. 
• It has a risk to both mother and fetus. 
• Eclampsia can be classified as antepartum, intrapartum and postpartum. 
• Tonic clonic seizures preceeded by premonitory stage in the form of 
facial and mouth twitching. 
• Major complications are abruption placenta,neurological 
deficit,aspiration pneumonitis,pulmonary edema,cardiopulmonary arrest 
and acute renal failure. 
Management of Eclampsia 
• First and Foremost is the effective resuscitation. 
• Nurse in semiprone position and immediately protect the airway  
• Give nasal oxygen and effective oral sucitioning to prevent aspiration 
pneumonitis. 
• Convulsions are controlled by giving intravenous loading dose of 
magnesium sulphate followed by intramuscular maintenance dose of 
magnesium sulphate.Intravenous dose 4g iv dose of 20% magnesium 
sulphate over 5-10 minutes followed by 5g im dose of 50% magnesium 
sulphate should be given on both buttocks followed by maintenance dose 
of 5g im every 4 hours over 24 hours.Monitor for magnesium sulphate 
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toxicity and to continue maintenance dose after ensuring presence of 
patellar reflex,respiratory rate and urineoutput.Magnesium sulphate 
toxicity is treated with intravenous 1g of 10% solution of calcium 
gluconate. 
• Antihypertensives should be initiated to control the blood pressure. 
• Avoid fluid overload.Diuretics are indicated only in pulmonary edema. 
• Blood sample should be sent for plateletcount, liver function test and 
renal function test. 
• After stabilising the patient, pregnancy is terminated. 
• Based on obstetric indications mode of delivery is planned. 
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HELLP Syndrome 
This is a severe form of preeclampsia. 
Diagnostic Criteria 
• Hemolysis 
• Elevated liver enzymes 
• Low platelet count 
• Abnormal blood smear 
• LDH >600IU/L 
• AST >70IU/L 
• Elevated indirect bilirubin 
According to MISISSIPPI Classification 
Class 1 [severe]  -AST or ALT >70U/L 
 LDH> 600U/L 
 Platelets <50-100 *10
9
U/L 
Class 2 [moderate]- AST or ALT >70U/L 
LDH >600U/L 
                                 Platelets >50-100 *10
9
U/L 
Class 3 [mild] - AST or ALT >40U/L 
LDH >600U/L 
Platelets 100-150 *10
9
U/L 
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Symptoms 
• Right upper quadrant or epigastric pain 
• Nausea,vomiting 
• Headache 
• Visual changes 
• Jaundice 
 
Figure 6 indicates abdominal CT Showing a subcapsular haematoma in a 
woman with HELLP syndrome 
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Complications 
• Placental abruption 
• DIC 
• Acute renal failure 
• Severe ascites 
• Cerebral edema 
• Pulmonary edema 
• Wound hematoma 
• Subcapsular liver hematoma 
• Liver rupture 
 
Management of HELLP Syndrome 
• Deliver rather than expectant management for pregnancies more than 
34weeks 
• For pregnancies less than 34 weeks deliver after a course of 
steroids.Steroids enhance the fetal lung maturity and improve the 
maternal platelet count. 
• Other tried modalities in HELLP syndrome are antithrombotics,dialysis, 
plasma exchange with FFP and plasmapheresis. 
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Preventive Measures of Preeclampsia 
• No role of sodium restriction in the prevention of preeclampsia and salt 
restriction is not recommended. 
• Antioxidants also not recommended. 
• No role of diuretics in the prevention. 
• According to some studies supplementation of low dose aspirin found to 
reduce the incidence of IUGR and preterm labour,19% reduction in risk 
of preeclampsia, 16%reduction in risk of fetal or neonatal deaths. 
• Low calcium intake increases blood pressure by stimulating release of 
parathyroid hormone which increases intracellular calcium in vascular 
smooth muscle and vasoconstriction and extracellular ionized calcium is 
necessary for the production of nitric oxide and regulation of vascular 
tone,hence calcium supplementation found to reduce the risk of 
preeclampsia in high risk population and in women with low intake of 
dietary calcium. 
• No randomized trials for heparin or low molecular weight heparin,hence 
not recommended. 
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Various studies have shown that serum uric acid plays an important role 
in the pathogenesis of preeclampsia and serum uric is elevated in preeclampsia 
patients and its levels correlate with severity of the disease and associated with 
poor perinatal outcome 
 
According to recent studies estimation of serum uric acid in the first 
trimester can be used as a predictor of preeclampsia. 
1] Gianni Bellomo and Sandra Venanzi et al [2011] studied the 
prognostic significance of serum uric acid in women with gestational 
hypertension. 
Their studies shown that serum uric acid is a reliable predictor of 
preeclampsia 
They studied 206 primiparasreferred for recent onset of hypertension with 
asingleton pregnancy. 
Receiver operating curve analysis showed that serum uric at a 309umol/l 
predicted the development of preeclampsia with 87.7% sensitivity and93.3% 
specificity. 
In conclusion women with suspected hypertension in pregnancy serum 
uric acid >309µmol/L accurately predicted the development of preeclampsia. 
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2]Jeltsfe. S.Chossen and Hanna De Rayter studied the accuracy of 
determining serum uric acid before 25
th
 gestational week in predicting 
preeclampsia. 
3]Annabel.C at al studied the pathogenic role of uric acid in 
preeclampsia.He mentioned that preeclampsia which is characterised by 
widespread endothelial dysfunction andinflammation might be propagated by 
uric acid. 
4] Karla Periera and Cristine Knoppka studied the association between 
serum uric acid and severity of preeclampsia. 
They evaluated serum uric acid as a marker of severity of preeclampsia 
and found that concentration of serum uric acid in pregnant women with 
preeclampsia is associated with severity of the disease and it contributes to 
better monitoring of mother and new-born. 
5] Robert W. Power at al did a study on uric acid concentrations in early 
pregnancy among preeclamptic women with gestational hyperuricemia at 
delivery. He concluded his study by saying that maternal serum uric acid 
concentrations increased significantly from early pregnancy. 
Uric acid increase more rapidly across pregnancy in women who develop 
HPU preeclampsia and HU pregnant women after 25 weeks of gestation 
compared with control pregnant women. 
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6]Bain Bridge[2008] at al in his study described the pathogenic role of 
uric acid in preeclampsia. 
7]Robert JM at al studied that maternal xanthine oxidase as a source of 
free radical and uric acid generation in preeclampsia.He found that increased 
xanthine oxidase in the skin of preeclamptic women. 
8] Richard J. Johnson andMehmet Kanbay at al studied that estimation of 
serum uric acid is a clinically useful marker to distinguish preeclampsia from 
gestational hypertension. 
In his studies he stated that elevated uric acid has 8-9 fold risk for 
preeclampsia, 1.6-1.7 fold increased risk for SGA and uric acid of 5.2mg/dl has 
excellent sensitivity and specificity and likelihood ratio for diagnosis and 
prognosis. 
9]Disha Sahijwani andAjeshDesal at al in his studies showed that serum 
uric acid as a prognostic marker of pregnancy induced hypertension. 
Retrospective study was done on 80 women of pregnancy induced 
hypertension including both gestational hypertension and preeclampsia from 
January 2011- march 2012. Results states that serum uric acid more than 6mg/dl 
is associated with maternal complications especially eclampsia and low 
birthweight. 
Page 43 of 102 
 
10]S.K.Laughon at al, J.Catov at al [2011] studied on first trimester 
serum uric acid and adverse pregnancy outcome.It is a prospective cohort study 
and the study among first trimester patients of about 1541. 
Over all 111 women developed gestational hypertension,60 women 
developed preeclampsia and 1370 women remained normotensive. 
Conclusion was higher uric acid in the first trimester associated with 
increasing risk of developing preeclampsia but not gestational 
hypertension.First trimester uric acid not related with preterm and small for 
gestational age. 
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Aim of the Study 
• To estimate whether an elevated uric acid level in the first trimester is 
associated with an increase in occurrence of preeclampsia. 
• To predict the cut off value of uric acid for the outcome preeclampsia. 
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Study design 
Prospective cohort study 
 
Study Period 
The study was carried out between November 2012 to November 2013. 
 
Inclusion Criteria 
1. All pregnant women with single ton gestation 
2. With LMP and USG confirmed pregnancy <13 weeks of gestation. 
 
Exclusion Criteria 
1. Women with chronic hypertension 
2. Women with H/o renal disorders 
3. Women with H/o gout. 
4. Women with H /o diabetes 
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Sample Size 
Sample size is calculated by using the following formula: 
Sample size n = [DEFF*Np(1-p)]/ [(d
2
/Z
2
1-α/2*(N-1)+p*(1-p) 
First trimester registered antenatal patients approximately is 1000 
I have assumed elevation of serum uric among antenatal population is 
20%,since study related is not available. 
Population size [for finite population correction factor fpc][N]:1000 
Hypothesized % frequency of outcome factor in the population[p]:20%+/-5 
Confidence limits as % of 100[absolute +/-%[d]:5% 
Design effect [for cluster surveys DEFF]:1 
Hence sample size for my study is 197 
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Methodology 
A total of 197 antenatal patients who attended the antenatal clinic of the 
department of obstetrics and gynaecology,Government Kilpauk Medical 
College,were selected based on inclusion and exclusion criteria after obtaining 
their consent. 
All selected women were subjected to a detailed history comprising of 
age,parity,body weight and height,LMP, medical history,drug history,previous 
obstetric history,previous H/o preeclampsia. 
They were subjected to clinical examination and BP was recorded. 
Routine laboratory investigations were done. 
On the next day fasting sample was taken from these patients for 
measuring serum uric acid level.Serum uric acid was measured by autoanalyzer. 
• These patients were regularly followed up in the antenatal OP once in 4 
weeks till 28 weeks then once in two weeks till their delivery and 
thorough clinical examination were done focusing their blood pressure 
and urine albumin.All details were entered.The patients who developed 
preeclampsia were grouped as preeclampsia cohort. 
• The patients who were normotensive till delivery were grouped as normal 
cohort. 
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• The factors taken for analysis were age distribution, obstetric score, body 
mass index, history of preeclampsia in previous pregnancies and the 
serum uric acid. 
• The predictive value of serum uric acid is determined by the ROC Curve. 
• Logistic regression model was used to estimate the causal effect of each 
predisposing factor on outcome and to find out the most effective 
predictor. 
Definitions used for the diagnosis of preeclampsia was according to 
International Society for the Study of Hypertension in Pregnancy 
[ISSHP],hypertension is defined as systolic blood pressure of >140 mmHg or 
diastolic blood pressure of >90mmHg. 
A rise in the systolic blood pressure of 30mmHg or rise in the diastolic 
blood pressure of 15mmHg, atleast 4 hours apart associated with proteinuria of 
at least1+ or 1g/L on dipstick. 
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Results of the Study 
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Age Distribution 
Table - 1 
Age In Years 
Preeclampsia Cohort Normal Cohort 
No. of Cases % No. of Cases  % 
<24 Years 9 56.25 114 62.98 
25-29 Years 5 31.25 50 27.63 
>30 Years 2 12.50 17 9.39 
Total 16 100 181 100 
 
Pearson Chi-Square test value is 0.802 
P value is 0.654  
 
56.25% of the patients in preeclampsia cohort and 62.98% of the patients in 
the normal cohort were in the age group of <24 years. 
31.25% of the patients in preeclampsia cohort and 27.63% of the patients in 
the normal cohort were in the age group of 25-29 years. 
12.50% of the patients in preeclampsia cohort and 9.39% of the patients in the 
normal cohort were in the age group of >30 years. 
 
 
 
 
  
 
Inference 
P value 0.654 is not significant. 
difference between preeclampsia & normal cohort with respect to age 
distribution. 
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Comparison of Age Vs Serum Uric Acid Level 
Table - 2 
Group Statistics 
Metrics No. Mean 
Std. 
Deviation 
Std. Error 
Mean 
Age 
serum uric acid 
greater than cut 
off value (4.9 
mg/dl) 
31 23.74 3.109 0.558 
serum uric acid 
within cut off 
value (4.9 mg/dl) 
166 23.83 3.586 0.278 
 
The mean age of the patients with elevated serum uric acid levels is 23.74. 
The mean age of the patients with normal serum uric acid levels is 23.83. 
There is no statistical significant difference between age and uric acid levels. 
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Comparison of Obstetric Score Vs Serum Uric Acid Level 
Table - 3 
Gravida and Serum Uric Acid value >4.9 mg/dl (cut off) 
Gravida Metrics 
Serum Uric Acid Level   
Within cut 
off value (4.9 
mg/dl) 
Greater than 
cut off value 
(4.9 mg/dl) 
Total 
1 
Count 111 18 129 
% within & 
greater than 
serum uric 
acid cut off 
value (4.9 
mg/dl) 
66.87% 58.06% 65.48% 
% of Total 56.35% 9.14% 65.48% 
2 
Count 45 10 55 
% within & 
greater than 
serum uric 
acid cut off 
value (4.9 
mg/dl) 
27.11% 32.26% 27.92% 
% of Total 22.84% 5.08% 27.92% 
3 
Count 9 2 11 
% within & 
greater than 
serum uric 
acid cut off 
value (4.9 
mg/dl) 
5.42% 6.45% 5.58% 
% of Total 4.57% 1.02% 5.58% 
4 
Count 1 1 2 
% within & 
greater than 
serum uric 
acid cut off 
value (4.9 
mg/dl) 
0.60% 3.23% 1.02% 
% of Total 0.51% 0.51% 1.02% 
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 Count 166 31 197 
  
% within & 
greater than 
serum uric 
acid cut off 
value (4.9 
mg/dl) 
100.00% 100.00% 100.00% 
Total % of Total 84.26% 15.74% 100.00% 
 
S. 
No. 
Parity 
No. 
of 
Cases 
% of 
Cases 
Uric 
Acid 
Level 
>4.9 
% of 
Cases 
Uric 
Acid 
Level 
<4.9 
% of 
Cases 
1 Primi 129 65.48% 18 9.14% 111 56.35% 
2 G2 55 27.92% 10 5.08% 45 22.84% 
3 G3 11 5.58% 2 1.02% 9 4.57% 
4 G4 2 1.02% 1 0.51% 1 0.51% 
 
Pearson Chi-Square test value is 2.378 
P value is 0.498 
 
 
 
 
 
 
 
 
 
  
Inference 
P value 0.498 is not significant. 
between serum uric acid levels with respect to obstetric score.
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Comparison of BMIVs Serum Uric Acid Level 
Table - 4 
Group Statistics 
Metrics No. Mean 
Std. 
Deviation 
Std. Error 
Mean 
BMI 
serum uric acid 
greater than cut 
off value (4.9 
mg/dl) 
31 22.27742 2.7518127 0.4942402 
serum uric acid 
within cut off 
value (4.9 mg/dl) 
166 22.1006 2.1384644 0.165977 
 
S. 
No. 
BMI 
No. of 
Cases 
% of 
Cases 
Uric Acid 
Level >4.9 
% of 
Cases 
Uric Acid 
Level <4.9 
% of 
Cases 
1 <25 179 90.86 23 12.85 156 87.15 
2 >25 18 9.14 8 44.44 10 55.56 
 
P value is 0.167 
 
 
  
Inference 
Mean BMI among patients with elevated uric acid
Mean BMI among patients with normal uric 
P value 0.167 is not significant. 
between BMI with respect to uric acid.
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Comparison of GAVs Serum Uric Acid Level 
Table - 5 
Group Statistics 
Metrics No. Mean 
Std. 
Deviation 
Std. Error 
Mean 
GA at 
sampling 
serum uric acid 
greater than 
cut off value 
(4.9 mg/dl) 
31 11.52 0.508 0.091 
serum uric acid 
within cut off 
value (4.9 
mg/dl) 
166 11.54 0.547 0.042 
 
P value is 0.494 
Inference 
Mean GA among patients with elevated uric acid levels is 11.52 
Mean GA among patients with normal uric acid levels is 11.54 
P value 0.494 is not significant. There is no statistical significant association 
between GA with respect to uric acid. 
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Correlation between Gestational Hypertension and Serum 
Uric Acid Level 
Table -6 
Gestation Hypertension and Serum Uric Acid value >4.9 mg/dl (cut off) 
Crosstab 
Condition Metrics 
Serum Uric Acid Level 
Total 
Within cut off 
value (4.9 
mg/dl) 
Greater than 
cut off value (4.9 
mg/dl) 
Gestation 
Hypertension = 
No 
Count 150 28 178 
% within & 
greater than 
serum uric acid 
cut off value 
(4.9 mg/dl) 
90.36% 90.32% 90.36% 
% of Total 76.14% 14.21% 90.36% 
Gestation 
Hypertension = 
Yes 
Count 16 3 19 
% within & 
greater than 
serum uric acid 
cut off value 
(4.9 mg/dl) 
9.64% 9.68% 9.64% 
% of Total 8.12% 1.52% 9.64% 
Total 
Count 166 31 197 
% within & 
greater than 
serum uric 
acid cut off 
value (4.9 
mg/dl) 
100.00% 100.00% 100.00% 
% of Total 84.26% 15.74% 100.00% 
 
S. 
No. 
Total No. of Cases 
who developed 
Gestational 
Hypertension 
% of 
Total 
Cases 
Uric Acid 
Level >4.9 
% of 
Cases 
Uric Acid 
Level <4.9 
% of 
Cases 
1 19 9.64 3 1.52 16 8.12 
 
  
Inference 
The mean serum uric acid level among patients with gestational hypertension in 
the first trimester is not high
P value 0.995 is not significant.
significantly associated with gestational hypertension.
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Correlation between Preeclampsia and Serum Uric 
AcidLevel 
Table - 7 
Preeclampsia and Serum Uric Acid value >4.9 mg/dl (cut off) 
Crosstab 
Condition Metrics 
Serum Uric Acid Level 
Total 
Within cut 
off value (4.9 
mg/dl) 
Greater 
than cut off 
value (4.9 
mg/dl) 
Preeclampsia = No 
Count 162 19 181 
% within & 
greater than 
serum uric acid 
cut off value 
(4.9 mg/dl) 
97.59% 61% 97.46% 
% of Total 82.23% 9.6% 97.46% 
Preeclampsia = Yes 
Count 4 12 16 
% within & 
greater than 
serum uric acid 
cut off value 
(4.9 mg/dl) 
2.41% 38.71% 41% 
% of Total 2.03% 6.09% 8.12% 
Total 
Count 166 31 197 
% within & 
greater than 
serum uric 
acid cut off 
value (4.9 
mg/dl) 
100.00% 100.00% 100.00% 
% of Total 84.26% 15.74% 100.00% 
 
S. 
No. 
Total No. of 
Patients who 
developed 
Preeclampsia 
% of 
Total 
Cases 
Uric Acid 
Level >4.9 
% of 
Cases 
Uric Acid 
Level <4.9 
% of 
Cases 
1 16 8.12 12 6.09 4 2.03 
  
 
Inference 
Prevalence of the preeclampsia from my study is 
Among those 12 (6%) patients 
developed preeclampsia. 
P value 0.0000001 is strongly significant
significantly associated with
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Correlation between HPU and Serum Uric Acid Level 
Table - 8 
HPU and Serum Uric Acid value >4.9 mg/dl (cut off) 
Crosstab 
Condition Metrics 
Serum Uric Acid Level 
Total 
Within cut 
off value 
(4.9 mg/dl) 
Greater 
than cut 
off value 
(4.9 mg/dl) 
HPU = No 
Count 166 19 185 
% within & 
greater 
than serum 
uric acid 
cut off 
value (4.9 
mg/dl) 
100.00% 61.29% 93.91% 
% of Total 84.26% 9.64% 93.91% 
HPU = 
Yes 
Count 0 12 12 
% within & 
greater 
than serum 
uric acid 
cut off 
value (4.9 
mg/dl) 
0.00% 38.71% 6.09% 
% of Total 0.00% 6.09% 6.09% 
 
 
 
 
Total 
Count 166 31 197 
% within 
& greater 
than 
serum uric 
acid cut 
off value 
(4.9 mg/dl) 
100.00% 100.00% 100.00% 
% of Total 84.26% 15.74% 100.00% 
 
 S. 
No. 
Total No. of 
Patients who 
developed HPU 
% of
Total 
Cases
1 12 6.09
 
 
Inference 
Prevalence of the HPU from my study is
Among those 12 (6%) patients 
developed HPU. 
P value 0.000 is strongly significant. Hyperuricemia in the first trimester is 
significantly associated with 
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Correlation betweenPreterm and Serum Uric Acid Level 
Table -9 
Preterm and Serum Uric Acid value >4.9 mg/dl (cut off) 
Crosstab 
Condition Metrics 
Serum Uric Acid Level 
Total 
Within cut off 
value (4.9 
mg/dl) 
Greater than 
cut off value 
(4.9 mg/dl) 
Preterm = No 
Count 154 27 181 
% within & 
greater than 
serum uric acid 
cut off value (4.9 
mg/dl) 
92.77% 87.10% 91.88% 
% of Total 78.17% 13.71% 91.88% 
 
 
 
Preterm = Yes 
Count 12 4 16 
% within & 
greater than 
serum uric acid 
cut off value (4.9 
mg/dl) 
7.23% 12.90% 8.12% 
% of Total 6.09% 2.03% 8.12% 
Total 
Count 166 31 197 
% within & 
greater than 
serum uric acid 
cut off value 
(4.9 mg/dl) 
100.00% 100.00% 100.00% 
% of Total 84.26% 15.74% 100.00% 
 
S. 
No. 
Total No. of 
Patients who 
delivered 
Preterm 
% of 
Total 
Cases 
Uric Acid 
Level >4.9 
% of 
Cases 
Uric Acid 
Level <4.9 
% of 
Cases 
1 16 8.12 4 2.03 12 6.09 
 
 
  
Inference 
P value 0.288 is not significant. There is no statistical significant association 
between hyperuricemia in the first trimester and preterm.
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Correlation between SGA and Serum Uric Acid Level 
Table - 10 
SGA and Serum Uric Acid value >4.9 mg/dl (cut off) 
Crosstab 
Condition Metrics 
Serum Uric Acid Level 
Total 
Within cut off 
value (4.9 
mg/dl) 
Greater than 
cut off value 
(4.9 mg/dl) 
SGA = No 
Count 157 27 184 
% within & 
greater than 
serum uric acid 
cut off value (4.9 
mg/dl) 
94.58% 87.10% 93.40% 
% of Total 79.70% 13.71% 93.40% 
 
 
SGA = Yes 
Count 9 4 13 
% within & 
greater than 
serum uric acid 
cut off value (4.9 
mg/dl) 
5.42% 12.90% 6.60% 
% of Total 4.57% 2.03% 6.60% 
Total 
Count 166 31 197 
% within & 
greater than 
serum uric acid 
cut off value 
(4.9 mg/dl) 
100.00% 100.00% 100.00% 
% of Total 84.26% 15.74% 100.00% 
 
S. 
No. 
Total No. of 
SGA Cases 
% of 
Total 
Cases 
Uric Acid 
Level >4.9 
% of 
Cases 
Uric Acid 
Level <4.9 
% of 
Cases 
1 13 6.60 4 2.03 9 4.57 
 
 
  
Inference 
P value 0.124 is not significant. There is
between hyperuricemia in the first trimester and SGA.
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 ROC curve 
Variable  
serum_uric_acid 
serum uric acid 
Classification 
variable 
HT_Hyperurecemia 
HT +Hyperurecemia 
   
Sample size 197 
Positive group HT+Hyperurecemia = 1 3 
Negative group HT+Hyperurecemia = 0 194 
 
Disease 
prevalence (%) Unknown 
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 Sensitivity: 100.0
 Specificity: 85.6
 Criterion : >4.9
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The receptor operating curve is used for clinical prediction rules. 
The accuracy of the curve is determined from the area under the curve. 
If the area under the curve is 0.9 -1then the accuracy is excellent. 
If the area under the curve is 0.8-0.9 the accuracy is good. 
Testing serum uric acid as a predictor of preeclampsia 
Area under the curve for uric acid is 0.92. 
Sensitivity:100% 
Specificity: 85.5%  
Criterion: 4.9 mg 
 
Area under the ROC curve (AUC) 
 
Area under the ROC curve (AUC)  0.92354 
Standard Error
a
 0.0345 
95% Confidence interval
b
 0.877143 to 0.956516 
Z Statistics 12.268 
Significance level P (Area=0.5) <0.0001 
a
DeLong et al., 1988 
b
 Binomial exact 
 
Youden index 
 
Youden index J 0.8557 
Associated criterion >4.9 
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Criterion values and coordinates of the ROC curve [Hide] 
   
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR 
≥2 100.00 29.2 - 100.0 0.00 0.0 - 1.9 1.00 0.00 
>2 100.00 29.2 - 100.0 1.55 0.3 - 4.5 1.02 0.00 
>2.1 100.00 29.2 - 100.0 2.58 0.8 - 5.9 1.03 0.00 
>2.2 100.00 29.2 - 100.0 4.12 1.8 - 8.0 1.04 0.00 
>2.3 100.00 29.2 - 100.0 5.15 2.5 - 9.3 1.05 0.00 
>2.4 100.00 29.2 - 100.0 9.28 5.6 - 14.3 1.10 0.00 
>2.5 100.00 29.2 - 100.0 12.89 8.5 - 18.4 1.15 0.00 
>2.6 100.00 29.2 - 100.0 13.40 8.9 - 19.0 1.15 0.00 
>2.7 100.00 29.2 - 100.0 15.98 11.1 - 21.9 1.19 0.00 
>2.8 100.00 29.2 - 100.0 21.65 16.1 - 28.1 1.28 0.00 
>2.9 100.00 29.2 - 100.0 27.32 21.2 - 34.2 1.38 0.00 
>3 100.00 29.2 - 100.0 32.99 26.4 - 40.1 1.49 0.00 
>3.1 100.00 29.2 - 100.0 35.57 28.8 - 42.7 1.55 0.00 
>3.2 100.00 29.2 - 100.0 44.85 37.7 - 52.1 1.81 0.00 
>3.22 100.00 29.2 - 100.0 45.36 38.2 - 52.6 1.83 0.00 
>3.3 100.00 29.2 - 100.0 46.39 39.2 - 53.7 1.87 0.00 
>3.4 100.00 29.2 - 100.0 51.03 43.8 - 58.3 2.04 0.00 
>3.5 100.00 29.2 - 100.0 57.22 49.9 - 64.3 2.34 0.00 
>3.6 100.00 29.2 - 100.0 58.25 51.0 - 65.3 2.40 0.00 
>3.7 100.00 29.2 - 100.0 63.92 56.7 - 70.7 2.77 0.00 
>3.8 100.00 29.2 - 100.0 68.04 61.0 - 74.5 3.13 0.00 
>3.9 100.00 29.2 - 100.0 68.56 61.5 - 75.0 3.18 0.00 
>4 100.00 29.2 - 100.0 74.23 67.5 - 80.2 3.88 0.00 
>4.1 100.00 29.2 - 100.0 77.32 70.8 - 83.0 4.41 0.00 
>4.2 100.00 29.2 - 100.0 77.84 71.3 - 83.5 4.51 0.00 
>4.3 100.00 29.2 - 100.0 80.93 74.7 - 86.2 5.24 0.00 
>4.4 100.00 29.2 - 100.0 81.44 75.2 - 86.7 5.39 0.00 
>4.5 100.00 29.2 - 100.0 81.96 75.8 - 87.1 5.54 0.00 
>4.6 100.00 29.2 - 100.0 82.47 76.4 - 87.5 5.71 0.00 
>4.9 100.00 29.2 - 100.0 85.57 79.8 - 90.2 6.93 0.00 
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>5 66.67 9.4 - 99.2 87.63 82.2 - 91.9 5.39 0.38 
>5.1 66.67 9.4 - 99.2 88.66 83.3 - 92.8 5.88 0.38 
>5.2 66.67 9.4 - 99.2 89.18 83.9 - 93.2 6.16 0.37 
>5.4 66.67 9.4 - 99.2 91.24 86.3 - 94.8 7.61 0.37 
>5.5 66.67 9.4 - 99.2 92.78 88.2 - 96.0 9.24 0.36 
>5.6 33.33 0.8 - 90.6 93.81 89.4 - 96.8 5.39 0.71 
>5.8 33.33 0.8 - 90.6 94.33 90.1 - 97.1 5.88 0.71 
>5.9 33.33 0.8 - 90.6 94.85 90.7 - 97.5 6.47 0.70 
>6 33.33 0.8 - 90.6 95.88 92.0 - 98.2 8.08 0.70 
>6.3 33.33 0.8 - 90.6 96.39 92.7 - 98.5 9.24 0.69 
>6.7 33.33 0.8 - 90.6 96.91 93.4 - 98.9 10.78 0.69 
>6.8 0.00 0.0 - 70.8 97.42 94.1 - 99.2 0.00 1.03 
>6.9 0.00 0.0 - 70.8 97.94 94.8 - 99.4 0.00 1.02 
>7 0.00 0.0 - 70.8 98.45 95.5 - 99.7 0.00 1.02 
>7.2 0.00 0.0 - 70.8 99.48 97.2 - 100.0 0.00 1.01 
>7.5 0.00 0.0 - 70.8 100.00 98.1 - 100.0 0.00 1.00 
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Summary 
• There is no statistical significance between BMI and serum uric acid 
level.The Mean BMI among patients with elevated serum uric acid level 
was 22.27 whereas the Mean BMI among patients with normal serum uric 
acid level was 22.10. 
• 66.87% of the patients in the normal cohort were primigravida,27.11% of 
the patients were second gravida, 5.42% of the patients were third gravida 
and 0.60% of the patients in the normal cohort were fourth gravida. 
• 58.06% of the patients with serum uric acid level >4.9 mg/dl were 
primigravida. 
• 32.26% of the patients with serum uric acid level >4.9 mg/dlwere second 
gravida. 
• 6.45% of the patients with serum uric acid level>4.9 mg/dlwere third 
gravida and 3.23% were fourth gravida. 
• The serum uric acid level was high in the patients who developed 
preeclampsia. 
• Area under the curve was 0.92. 
• Testing serum uric as a predictor sensitivity 100% and specificity was 
85.5%. 
• The mean cut off value of serum uric for the patients who developed 
preeclampsia is 4.9. 
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Discussion 
Our study included 197 first trimester pregnant women recruited from antenatal 
op department. 
• Over all 19 women [9.64%] developed gestational hypertension,16 
women[8%] developed preeclampsia and remaining 162 women[82.2%] 
were normotensive. 
• Prevalence of gestational hypertension from my study was 9.64%. 
• Prevalence of preeclampsia from my study was 8.12%. 
• There were 16 births [8.12%]that were delivered preterm <37 weeks of 
gestation. 
• The serum uric acid level among patients who delivered preterm was not 
high. 
• There were 13 neonates that were small for gestational age SGA [6.60%]  
• The mean serum uric level among patients who delivered small for 
gestational age was normal. 
• Only 15.79% of the patients who developed gestational hypertension 
have elevated serum uric acid levels. 
• Over all 16 [8.12%]women developed preeclampsia among them 12 
women [75%]women has high serum uric acid levels and 4 women [25%] 
have normal serum uric acid levels. 
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• The mean age of patients among elevated serum uric acid level was 23.74 
whereasthe mean age of patients with normal serum uric acid level was 
23.83. 
• No statistical significant difference between age and serum uric acid 
level. 
• No statistical significant difference between BMI and serum uric acid 
level. 
My study is similar to the study of S.K. Laughon and J.Catov on first trimester 
serum uric acid and adverse pregnancy outcome[2011] 
 
 
 
S. No. Parameter My Study S.K.Laughon and 
J.Catov 
1. Age and serum 
uric acid 
No statistical 
significant 
difference 
No statistical 
significant difference 
2. BMI and uric acid No statistical 
significant 
difference 
No statistical 
significant difference 
3. Gestational  
Hypertension and 
hyperuricemia 
Not strongly 
associated. 
Only 15% 
Only 20% associated 
with hyperuricemia 
4 preeclampsia Strongly 
associated 
75%  
Strongly associated 
53.3% 
5. Preterm No linear 
association 
No linear  association 
6. SGA No linear 
association 
No linear association 
7. Uric acid status at 
delivery 
Not known Uric acid sample was 
taken at delivery. 
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Conclusion 
After analysing and comparing the results between preeclampsia cohort and 
normal cohort it was concluded that: 
• The serum uric acid level was high among preeclampsia patients in the 
first trimester. 
• Thus there exists a positive correlation between elevated serum uric acid 
level in the first trimester and occurrence of preeclampsia. 
• The mean cut off value of serum uric acid level for the prediction of 
preeclampsia in my study is 4.9 
• There is no positive correlation between body mass index and serum uric 
acid level. 
• There is no linear association between preterm & elevated serum uric 
acid level.Similarly there is no linear association between small for 
gestational age and uric acid level. 
• Therefore serum uric acid level in the first trimester can be a good 
predictor for preeclampsia if we combine with other clinical and 
biochemical parameters to improve the prediction. 
• Long term cohort studies are needed to investigate whether patients with 
hyperuricemia early in pregnancy are at risk for developing hypertensive 
diseases with more adverse outcomes during pregnancy and future risk of 
metabolic syndrome, cardiovascular disease,diabetes and hypertension. 
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Master Chart 
S. 
No Name Age Parity BMI 
GA at sampling Previous H/o Preeclampsia 
Previous H/o Chronic Hypertension   BP 
1 Kanchana 24 G4P1L1A2 24 11WKS 110/70 
2 Devi 24 PRIMI 22 12WKS 120/70 
3 Bhavana 30 G3P1L1A1 22 12WKS 110/70 
4 Thenmozhi 20 PRIMI 20.5  11WKS 100/70 
5 Rama 21 PRIMI 20.5 10WKS 90/60 
6 Revathy 23 PRIMI 21 11WKS 110/70 
7 Rasathy 28 primi 23 12wks 120/80 
8 Deepa 24 G2P1L1 24 12WKS 100/70 
9 Sangeetha 28 PRIMI 22 12WKS 110/80 
10 Vijayalakshmi 28 PRIMI 25 12WKS 120/80 
11 Vijayalakshmi 20 PRIMI 22 12WKS 100/80 
12 Shajitha 24 PRIMI 21.5 11WKS 120/80 
13 Mala 26 G2P1L1 24 12WKS 110/80 
14 Sudha 22 PRIMI 22 12WKS 100/70 
15 Kalaiselvi 20 PRIMI 20 11WKS 120/80 
16 Bhoomadevi 22 PRIMI 21 12WKS 100/70 
17 Mohana 21 PRIMI 21.5 10WKS 100/60 
18 Thenmozhi 25 PRIMI 22 11WKS 100/60 
19 Meenakshi 24 PRIMI 23 12WKS 100/70 
20 Vidhya 31 G3P1L1A1 24.5 12WKS 110/70 
21 Lakshmi 25 PRIMI 22 11WKS 110/80 
22 Suguna 20 PRIMI 21 11WKS 120/80 
23 Anushya 20 PRIMI 22 11WKS 120/80 
24 Priya 22 PRIMI 23 12WKS 110/70 
25 Rajeshwari 37 G3P1L1A1 24 12WKS 110/70 
26 Muthukumari 22 PRIMI 22.5 11WKS 100/70 
27 Suganya 27 G2P1L1 22 12WKS 100/70 
28 Selvi 22 G2P1L1 21 11WKS 100/70 
29 Renuka 20 PRIMI 20.5 12WKS 120/80 
30 Kiladha 21 PRIMI 22.5 12WKS 100/80 
31 Gomathy 27 G2P1L1 24 11WKS 100/80 
32 Sumathy 20 PRIMI 21 11WKS 120/80 
33 Revthy 27 G2P1L1 22.5 11WKS 120/80 
34 Sathya 23 PRIMI 23.5 12WKS 100/70 
35 Bhagya 25 PRIMI 22 12WKS 120/80 
36 Karpagam 22 PRIMI 22 12WKS 100/80 
37 Manju 27 G2P1L1 22.5 12WKS `120/80 
38 Meenakshi 20 PRIMI 21 11WKS 100/80 
39 Naheshwari 20 PRIMI 21.5 11WKS 100/80 
40 Sundari 22 PRIMI 21.5 11WKS 120/80 
41 Benazir 20 PRIMI 22 12WKS 100/70 
42 Nadhiya 21 PRIMI 22.5 12WKS 120/80 
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S. 
No Name Age 
Previous H/o 
Preeclampsia 
Previous H/o 
Chronic Hypertension 
Previous H/o 
Gout 
Serum Uric 
Acid 
1 Kanchana 24 0 0 0 3.1mg 
2 Devi 24 0 0 0 3.1mg 
3 Bhavana 30 0 0 0 2.9mg 
4 Thenmozhi 20 0 0 0 2.9mg 
5 Rama 21 0 0 0 2.9mg 
6 Revathy 23 0 0 0 2.9mg 
7 Rasathy 28 0 0 0 3.5mg 
8 Deepa 24 0 0 0 3.4mg 
9 Sangeetha 28 0 0 0 2.4mg 
10 Vijayalakshmi 28 0 0 0 2.9mg 
11 Vijayalakshmi 20 0 0 0 2.9mg 
12 Shajitha 24 0 0 0 5.6mg 
13 Mala 26 0 0 0 3.8mg 
14 Sudha 22 0 0 0 6.8mg 
15 Kalaiselvi 20 0 0 0 3.0mg 
16 Bhoomadevi 22 0 0 0 3.4mg 
17 Mohana 21 0 0 0 3.0mg 
18 Thenmozhi 25 0 0 0 3.5mg 
19 Meenakshi 24 0 0 0 3.7mg 
20 Vidhya 31 0 0 0 2.3mg 
21 Lakshmi 25 0 0 0 7.5mg 
22 Suguna 20 0 0 0 2.0mg 
23 Anushya 20 0 0 0 2.7mg 
24 Priya 22 0 0 0 4.1mg 
25 Rajeshwari 37 0 0 0 3.0mg 
26 Muthukumari 22 0 0 0 2.1mg 
27 Suganya 27 0 0 0 3.7mg 
28 Selvi 22 0 0 0 5.1mg 
29 Renuka 20 0 0 0 5.5mg 
30 Kiladha 21 0 0 0 3.3mg 
31 Gomathy 27 0 0 0 3.0mg 
32 Sumathy 20 0 0 0 3.2mg 
33 Revthy 27 0 0 0 4.0mg 
34 Sathya 23 0 0 0 3.9mg 
35 Bhagya 25 0 0 0 2.4mg 
36 Karpagam 22 0 0 0 6.0mg 
37 Manju 27 0 0 0 2.2mg 
38 Meenakshi 20 0 0 0 2.5mg 
39 Naheshwari 20 0 0 0 3.8mg 
40 Sundari 22 0 0 0 3.4mg 
41 Benazir 20 0 0 0 2.8mg 
42 Nadhiya 21 0 0 0 4.3mg 
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S. 
No Name Age Roll Over Test 
Urine 
Albumin RFT LFT 
Gestation 
Hypertension Preeclampsia 
1 Kanchana 24   nil N N 0 0 
2 Devi 24   nil N N 0 0 
3 Bhavana 30 positive nil N N 1 0 
4 Thenmozhi 20   nil N N 0 0 
5 Rama 21   nil N N 0 0 
6 Revathy 23   nil N N 0 0 
7 Rasathy 28   nil N N 0 0 
8 Deepa 24 positive 2+ N N 0 1 
9 Sangeetha 28 positive nil N N 1 0 
10 Vijayalakshmi 28   nil NN N 0 0 
11 Vijayalakshmi 20   nil N N 0 0 
12 Shajitha 24 positive nil N N 1 0 
13 Mala 26   nil N N 0 0 
14 Sudha 22 positive 3+ N N 0 0 
15 Kalaiselvi 20   nil N N 0 0 
16 Bhoomadevi 22 positive nil N N 1 0 
17 Mohana 21   nil N N 0 0 
18 Thenmozhi 25   nil N N 0 0 
19 Meenakshi 24   nil N N 0 0 
20 Vidhya 31   nil N N 0 0 
21 Lakshmi 25 positive 3+ N N 0 1 
22 Suguna 20   nil N N 0 0 
23 Anushya 20   nil N N 0 0 
24 Priya 22   nil N N 0 0 
25 Rajeshwari 37 positive 2+ N N 0 1 
26 Muthukumari 22   nil N N 0 0 
27 Suganya 27   nil N N 0 0 
28 Selvi 22   nil N N 0 0 
29 Renuka 20 positive 2+ N N 0 0 
30 Kiladha 21   nil N N 0 0 
31 Gomathy 27 positive 2+ N N 0 1 
32 Sumathy 20 positive nil N N 1 0 
33 Revthy 27   nil N N 0 0 
34 Sathya 23   nil N N 0 0 
35 Bhagya 25   nil N N 0 0 
36 Karpagam 22 positive 3+ N N 0 0 
37 Manju 27   nil N N 0 0 
38 Meenakshi 20   nil N N 0 0 
39 Naheshwari 20   nil N N 0 0 
40 Sundari 22   nil N N 0 0 
41 Benazir 20   nil N N 0 0 
42 Nadhiya 21   nil N N 0 0 
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S. 
No Name Age 
HT+ 
Hyperurecemia HPU Preterm SGA 
GA at 
whichPreeclampsia is 
detected  GA at Delivery 
1 Kanchana 24 0 0 1 0     
2 Devi 24 0 0 0 0     
3 Bhavana 30 0 0 0 0   39WKS 
4 Thenmozhi 20 0 0 0 0     
5 Rama 21 0 0 0 0     
6 Revathy 23 0 0 0 0     
7 Rasathy 28 0 0 0 0     
8 Deepa 24 0 0 0 0 37WKS 37WKS 
9 Sangeetha 28 0 0 0 0     
10 Vijayalakshmi 28 0 0 0 0     
11 Vijayalakshmi 20 0 0 0 0     
12 Shajitha 24 1 0 0 0   39WKS 
13 Mala 26 0 0 0 0     
14 Sudha 22 0 1 0 1 37WKS 37WKS 
15 Kalaiselvi 20 0 0 0 0     
16 Bhoomadevi 22 0 0 0 0   39WKS 
17 Mohana 21 0 0 0 1     
18 Thenmozhi 25 0 0 0 0     
19 Meenakshi 24 0 0 1 0     
20 Vidhya 31 0 0 0 1     
21 Lakshmi 25 0 1 1 1 36WKS 36WKS 
22 Suguna 20 0 0 0 0     
23 Anushya 20 0 0 1 0     
24 Priya 22 0 0 1 0     
25 Rajeshwari 37 0 0 0 0 38WKS 38WKS 
26 Muthukumari 22 0 0 0 1     
27 Suganya 27 0 0 0 0     
28 Selvi 22 0 0 0 0     
29 Renuka 20 0 1 0 0 37WKS2DAYS 37WKS 2DAYS 
30 Kiladha 21 0 0 1 0     
31 Gomathy 27 0 0 0 0   38WKS 
32 Sumathy 20 0 0 0 0   39WKS 
33 Revthy 27 0 0 0 0     
34 Sathya 23 0 0 0 0     
35 Bhagya 25 0 0 0 0     
36 Karpagam 22 0 1 1 0 37WKS 37WKS 
37 Manju 27 0 0 0 0     
38 Meenakshi 20 0 0 0 0     
39 Naheshwari 20 0 0 0 0     
40 Sundari 22 0 0 0 0     
41 Benazir 20 0 0 0 0     
42 Nadhiya 21 0 0 0 0     
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S. 
No Name Age Parity BMI 
GA at sampling Previous H/o Preeclampsia 
Previous H/o Chronic Hypertension   BP 
43 Mary 21 PRIMI 22.5 12WKS 120/80 
44 Varalakshmi 20 PRIMI 21 12WKS 100/80 
45 Seetha 24 G2P1L1 23 11WKS 100/70 
46 Durga 24 G2P1L1 23 11WKS 110/80 
47 Valli 24 G2P1L1 22.5 12WKS 100/80 
48 Vanitha 28 PRIMI 23.5 12WKS 100/70 
49 Selvi 20 PRIMI 20.5 12WKS 100/70 
50 Renuka 23 PRIMI 22 12WKS 100/70 
51 Kiladha 25 PRIMI 22 12WKS 100/70 
52 Anjali 27 G2P1L1 23.5 11WKS 100/70 
53 Manivijaya 20 PRIMI 23 11WKS 120/70 
54 Ravathy 27 G2P1L1 24 12WKS 100/70 
55 Valarmathy 21 PRIMI 20 12WKS 120/80 
56 Gomathy 25 PRIMI 22 11WKS 100/80 
57 Amul 25 G2P1L1 22 11WKS 120/80 
58 Devi 25 G2P1L1 20 12WKS 100/80 
59 Adhilakshmi 29 G2P1L1 27 12WKS 100/70 
60 Dhanakodi 24 G2P1L1 24 12WKS 120/80 
61 Gayathri 28 PRIMI 20 12WKS 100/80 
62 Radhika 27 G3P2L2 24 11WKS 120/80 
63 Suganthi 22 G2A1 21 11WKS 120/80 
64 Vasanthi 21 G2A1 23 12WKS 120/80 
65 Babitha 24 PRIMI 22 12WKS 110/80 
66 Soniya 22 PRIMI 21 11WKS 120/80 
67 Vanitha 27 G2P1L1 24 12WKS 110/80 
68 Pachiyammal 26 PRIMI 20.4 11WKS 110/80 
69 Suganya 21 PRIMI 21.8 11WKS 110/80 
70 Bhuvaneshwari 21 PRIMI 24.6 11WKS 110/70 
71 Malathy 30 G3P2L2 26.3 12WKS 100/70 
72 Gayathri 21 G2A1 23.8 12WKS 110/80 
73 Indumathy 20 PRIMI 22 12WKS 110/80 
74 Revathy 22 PRIMI 21.5 12WKS 110/80 
75 Ashwini 24 G3P2L2 17.7 12WKS 110/80 
76 Jennifer 25 PRIMI 17.8 11WKS 100/70 
77 Sudha 25 G2P1L1 23.5 12WKS 110/70 
78 Vidhya 22 PRIMI 19 11WKS 110/70 
79 Asha 26 G2P1L1 23.5 12WKS 110/70 
80 Gomathy 21 G3P1L1A1 22 12WKS 110/70 
81 Jeeva 24 PRIMI 23 11WKS 110/70 
82 Thayamma 26 G3P2L2 23.5 12WKS 110/70 
83 Dhanam 30 G3P2L2 24 11WKS 110/70 
84 Vijayalakshmi 28 PRIMI 19 12WKS 100/70 
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S. 
No Name Age 
Previous H/o 
Preeclampsia 
Previous H/o 
Chronic Hypertension 
Previous 
H/oGout 
Serum Uric 
Acid 
43 Mary 21 0 0 0 2.2mg 
44 Varalakshmi 20 0 0 0 4.3mg 
45 Seetha 24 0 0 0 2.5mg 
46 Durga 24 0 0 0 6.7mg 
47 Valli 24 0 0 0 4.1mg 
48 Vanitha 28 0 0 0 3.4mg 
49 Selvi 20 0 0 0 3.2mg 
50 Renuka 23 0 0 0 3.0mg 
51 Kiladha 25 0 0 0 5.0mg 
52 Anjali 27 0 0 0 2.8mg 
53 Manivijaya 20 0 0 0 5.2mg 
54 Ravathy 27 0 0 0 3.0mg 
55 Valarmathy 21 0 0 0 3.2mg 
56 Gomathy 25 0 0 0 4.0mg 
57 Amul 25 0 0 0 4.2mg 
58 Devi 25 0 0 0 3.7mg 
59 Adhilakshmi 29 0 0 0 5.4mg 
60 Dhanakodi 24 0 0 0 2.5mg 
61 Gayathri 28 0 0 0 3.7mg 
62 Radhika 27 0 0 0 5.6mg 
63 Suganthi 22 0 0 0 2.7mg 
64 Vasanthi 21 0 0 0 2.8mg 
65 Babitha 24 0 0 0 3.7mg 
66 Soniya 22 0 0 0 3mg 
67 Vanitha 27 0 0 0 2.4mg 
68 Pachiyammal 26 0 0 0 5.0mg 
69 Suganya 21 0 0 0 4.1mg 
70 Bhuvaneshwari 21 0 0 0 4.0mg 
71 Malathy 30 0 0 0 5.9mg 
72 Gayathri 21 0 0 0 3.5mg 
73 Indumathy 20 0 0 0 4.3mg 
74 Revathy 22 0 0 0 3.5mg 
75 Ashwini 24 0 0 0 4.1mg 
76 Jennifer 25 0 0 0 3.7mg 
77 Sudha 25 0 0 0 7mg 
78 Vidhya 22 0 0 0 2.6mg 
79 Asha 26 0 0 0 5.4mg 
80 Gomathy 21 0 0 0 4mg 
81 Jeeva 24 0 0 0 3.0mg 
82 Thayamma 26 0 0 0 4.9mg 
83 Dhanam 30 0 0 0 3.5mg 
84 Vijayalakshmi 28 0 0 0 2.5mg 
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S. 
No Name Age Roll Over Test 
Urine 
Albumin RFT LFT 
Gestation 
Hypertension Preeclampsia 
43 Mary 21   nil N N 0 0 
44 Varalakshmi 20   nil N N 0 0 
45 Seetha 24   nil N N 0 0 
46 Durga 24 positive 2+ N N 0 0 
47 Valli 24   nil N N 0 0 
48 Vanitha 28 positive nil N N 1 0 
49 Selvi 20   nil N N 0 0 
50 Renuka 23   nil N N 0 0 
51 Kiladha 25 positive nil N N 1 0 
52 Anjali 27 positive nil N N 1 0 
53 Manivijaya 20   nil N N 0 0 
54 Ravathy 27 positive nil N N 1 0 
55 Valarmathy 21   nil N N 0 0 
56 Gomathy 25   nil N N 0 0 
57 Amul 25   nil N N 0 0 
58 Devi 25   nil N N 0 0 
59 Adhilakshmi 29   nil N N 0 0 
60 Dhanakodi 24   nil N N 0 0 
61 Gayathri 28   nil N N 0 0 
62 Radhika 27   nil N N 0 0 
63 Suganthi 22   nil N N 0 0 
64 Vasanthi 21   nil N N 0 0 
65 Babitha 24   nil N N 0 0 
66 Soniya 22   nil N N 0 0 
67 Vanitha 27   nil N N 0 0 
68 Pachiyammal 26   nil N N 0 0 
69 Suganya 21   nil N N 0 0 
70 Bhuvaneshwari 21   nil N N 0 0 
71 Malathy 30   nil N N 0 0 
72 Gayathri 21   nil N N 0 0 
73 Indumathy 20   nil N N 0 0 
74 Revathy 22   nil N N 0 0 
75 Ashwini 24   nil N N 0 0 
76 Jennifer 25   nil N N 0 0 
77 Sudha 25 positive 3+ N N 0 0 
78 Vidhya 22   nil N N 0 0 
79 Asha 26   nil N N 0 0 
80 Gomathy 21   nil N N 0 0 
81 Jeeva 24   nil N N 0 0 
82 Thayamma 26   nil N N 0 0 
83 Dhanam 30 positive nil N N 1 0 
84 Vijayalakshmi 28   nil N N 0 0 
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S. 
No Name Age 
HT+ 
Hyperurecemia HPU Preterm SGA 
GA at 
whichPreeclampsia is 
detected  GA at Delivery 
43 Mary 21 0 0 1 0     
44 Varalakshmi 20 0 0 0 0     
45 Seetha 24 0 0 0 0     
46 Durga 24 0 1 0 1 38WKS 38WKS 
47 Valli 24 0 0 0 0     
48 Vanitha 28 0 0 0 0   40WKS 
49 Selvi 20 0 0 0 1     
50 Renuka 23 0 0 0 0     
51 Kiladha 25 1 0 0 0   39WKS 
52 Anjali 27 0 0 0 0   39WKS 
53 Manivijaya 20 0 0 0 0     
54 Ravathy 27 0 0 1 0   39WKS 
55 Valarmathy 21 0 0 0 0     
56 Gomathy 25 0 0 0 0     
57 Amul 25 0 0 0 0     
58 Devi 25 0 0 0 0     
59 Adhilakshmi 29 0 0 0 0     
60 Dhanakodi 24 0 0 0 0     
61 Gayathri 28 0 0 0 0     
62 Radhika 27 0 0 0 0     
63 Suganthi 22 0 0 0 0     
64 Vasanthi 21 0 0 0 0     
65 Babitha 24 0 0 0 0     
66 Soniya 22 0 0 0 0     
67 Vanitha 27 0 0 0 0     
68 Pachiyammal 26 0 0 0 0     
69 Suganya 21 0 0 0 0     
70 Bhuvaneshwari 21 0 0 0 0     
71 Malathy 30 0 1 0 0 37WKS3DAYS 37WKS 3DAYS 
72 Gayathri 21 0 0 0 0     
73 Indumathy 20 0 0 0 0     
74 Revathy 22 0 0 0 0     
75 Ashwini 24 0 0 0 0     
76 Jennifer 25 0 0 0 0     
77 Sudha 25 0 1 1 1 34WKS 34WKS2D 
78 Vidhya 22 0 0 1 0     
79 Asha 26 0 0 0 0     
80 Gomathy 21 0 0 0 0     
81 Jeeva 24 0 0 0 0     
82 Thayamma 26 0 0 0 0     
83 Dhanam 30 0 0 0 0   39WKS 
84 Vijayalakshmi 28 0 0 0 0     
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S. 
No Name Age Parity BMI 
GA at sampling Previous H/o Preeclampsia 
Previous H/o Chronic Hypertension   BP 
85 Revathy 21 PRIMI 26.8 12WKS 100/70 
86 Bhavani 21 PRIMI 22 11WKS 120/70 
87 Lakshmi 23 G2P1L1 18 12WKS 120/70 
88 Geetha 26 G2P1L1 24.2 11WKS 120/70 
89 Nisha 24 PRIMI 22.9 12WKS 110/70 
90 Leela 27 PRIMI 30.5 11WKS 110/70 
91 Sowmya 21 PRIMI 21.5 12WKS 120/70 
92 Sudha 25 PRIMI 22 11WKS 120/70 
93 Soniya 24 PRIMI 22 11WKS 120/70 
94 Senthamizh 20 G2P1L1 21 12WKS 120/70 
95 Uma 21 PRIMI 21 11WKS 120/70 
96 Rohini 20 PRIMI 20 12WKS 110/70 
97 Rajeshwari 26 G2P1L1 18.4 11WKS 120/70 
98 Dhivya 26 PRIMI 21.3 12WKS 120/70 
99 Chitra 19 PRIMI 20 11WKS 110/80 
100 Mubasheera 28 PRIMI 24.4 11WKS 110/80 
101 Poongavanam 21 PRIMI 19.6 11WKS 110/80 
102 Nalini 19 G2P1L1 23.8 12WKS 110/80 
103 Latha 26 G2P1LO 25 11WKS 120/80 
104 Srrenidhi 21 G2A1 20 12WKS 120/80 
105 Devaki 24 PRIMI 22 11WKS 110/70 
106 Santha 26 PRIMI 17.4 12WKS 110/70 
107 Prema 21 PRIMI 20 11WKS 110/70 
108 Anuradha 32 G2P1L1 20 12WKS 110/70 
109 Kavitha 21 PRIMI 22.3 11WKS 110/70 
110 Rukmani 25 PRIMI 22.3 12WKS 110/70 
111 Revathy 24 PRIMI 20 11WKS 110/70 
112 Rukmani 25 PRIMI 25.5 12WKS 110/70 
113 Rekha 24 PRIMI 21 11WKS 110/70 
114 Megala 27 PRIMI 21 11WKS 120/70 
115 Selvi 23 G2P1L1 28.1 11WKS 120/80 
116 Viji 31 G2P1L1 16 12WKS 120/70 
117 Shanthi 22 PRIMI 29.5 11WKS 120/80 
118 Lalitha 20 PRIMI 20.3 12WKS 120/70 
119 Sasikala 38 G2P1L1 25.5 11WKS 120/70 
120 Jothi 30 G3P1L1A1 17.7 12WKS 120/80 
121 Sugam 20 PRIMI 18 12WKS 120/80 
122 Selvi 20 PRIMI 22.5 11WKS 120/80 
123 Bhavani 39 PRIMI 18.4 12WKS 110/80 
124 Jaya 21 G2A1 20 11WKS 110/80 
125 Kokila 27 G2P1L1 18.4 12WKS 110/80 
126 Shanthi 20 PRIMI 20 12WKS 110/80 
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S. 
No Name Age 
Previous H/o 
Preeclampsia 
Previous H/o 
Chronic Hypertension 
Previous 
H/oGout 
Serum Uric 
Acid 
85 Revathy 21 0 0 0 3.7mg 
86 Bhavani 21 0 0 0 2.4mg 
87 Lakshmi 23 0 0 0 5.0mg 
88 Geetha 26 0 0 0 4.0mg 
89 Nisha 24 0 0 0 3.8mg 
90 Leela 27 0 0 0 4.3mg 
91 Sowmya 21 0 0 0 5.5mg 
92 Sudha 25 0 0 0 3.5mg 
93 Soniya 24 0 0 0 3.2mg 
94 Senthamizh 20 0 0 0 4.1mg 
95 Uma 21 0 0 0 4.6mg 
96 Rohini 20 0 0 0 2.8mg 
97 Rajeshwari 26 0 0 0 4.9mg 
98 Dhivya 26 0 0 0 4.9mg 
99 Chitra 19 0 0 0 7.2mg 
100 Mubasheera 28 0 0 0 5.0mg 
101 Poongavanam 21 0 0 0 2.8mg 
102 Nalini 19 0 0 0 4.0mg 
103 Latha 26 0 0 0 6.9mg 
104 Srrenidhi 21 0 0 0 6.3mg 
105 Devaki 24 0 0 0 4.4mg 
106 Santha 26 0 0 0 2.4mg 
107 Prema 21 0 0 0 3.5mg 
108 Anuradha 32 0 0 0 2.5mg 
109 Kavitha 21 0 0 0 2.7mg 
110 Rukmani 25 0 0 0 2.5mg 
111 Revathy 24 0 0 0 4.3mg 
112 Rukmani 25 0 0 0 3.7mg 
113 Rekha 24 0 0 0 2.7mg 
114 Megala 27 0 0 0 2.7mg 
115 Selvi 23 0 0 0 3.4mg 
116 Viji 31 0 0 0 2.8mg 
117 Shanthi 22 0 0 0 2.8mg 
118 Lalitha 20 0 0 0 3.2mg 
119 Sasikala 38 0 0 0 3.2mg 
120 Jothi 30 0 0 0 3.8mg 
121 Sugam 20 0 0 0 5.8mg 
122 Selvi 20 0 0 0 2.7mg 
123 Bhavani 39 0 0 0 3.5mg 
124 Jaya 21 0 0 0 2.8mg 
125 Kokila 27 0 0 0 4.9mg 
126 Shanthi 20 0 0 0 7.2mg 
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S. 
No Name Age Roll Over Test 
Urine 
Albumin RFT LFT 
Gestation 
Hypertension Preeclampsia 
85 Revathy 21   nil N N 0 0 
86 Bhavani 21   nil N N 0 0 
87 Lakshmi 23   nil N N 0 0 
88 Geetha 26   nil N N 0 0 
89 Nisha 24   nil N N 0 0 
90 Leela 27   nil N N 0 0 
91 Sowmya 21   nil N N 0 0 
92 Sudha 25   nil N N 0 0 
93 Soniya 24   nil N N 0 0 
94 Senthamizh 20   nil N N 0 0 
95 Uma 21   nil N N 0 0 
96 Rohini 20   nil N N 0 0 
97 Rajeshwari 26   nil N N 0 0 
98 Dhivya 26   nil N N 0 0 
99 Chitra 19 positive 2+ N N 0 0 
100 Mubasheera 28   nil N N 0 0 
101 Poongavanam 21   nil N N 0 0 
102 Nalini 19   nil N N 0 0 
103 Latha 26 positive 2+ N N 0 0 
104 Srrenidhi 21   nil N N 0 0 
105 Devaki 24   nil N N 0 0 
106 Santha 26   nil N N 0 0 
107 Prema 21   nil N N 0 0 
108 Anuradha 32 positive nil N N 1 0 
109 Kavitha 21   nil N N 0 0 
110 Rukmani 25   nil N N 0 0 
111 Revathy 24   nil N N 0 0 
112 Rukmani 25   nil N N 0 0 
113 Rekha 24   nil N N 0 0 
114 Megala 27   nil N N 0 0 
115 Selvi 23   nil N N 0 0 
116 Viji 31 positive 2+ N N 0 1 
117 Shanthi 22   nil N N 0 0 
118 Lalitha 20   nil N N 0 0 
119 Sasikala 38 positive nil N N 1 0 
120 Jothi 30   nil N N 0 0 
121 Sugam 20 positive nil N N 0 0 
122 Selvi 20   nil N N 0 0 
123 Bhavani 39   nil N N 0 0 
124 Jaya 21   nil N N 0 0 
125 Kokila 27   nil N N 0 0 
126 Shanthi 20 positive 3+ N N 0 0 
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S. 
No Name Age 
HT+ 
Hyperurecemia HPU Preterm SGA 
GA at 
whichPreeclampsia is 
detected  GA at Delivery 
85 Revathy 21 0 0 0 0     
86 Bhavani 21 0 0 0 1     
87 Lakshmi 23 0 0 0 0     
88 Geetha 26 0 0 0 0     
89 Nisha 24 0 0 0 0     
90 Leela 27 0 0 0 0     
91 Sowmya 21 0 0 0 0     
92 Sudha 25 0 0 0 0     
93 Soniya 24 0 0 0 0     
94 Senthamizh 20 0 0 0 0     
95 Uma 21 0 0 0 0     
96 Rohini 20 0 0 1 1     
97 Rajeshwari 26 0 0 0 0     
98 Dhivya 26 0 0 0 0     
99 Chitra 19 0 1 1 0 35WKS 35WKS 
100 Mubasheera 28 0 0 0 0     
101 Poongavanam 21 0 0 0 0     
102 Nalini 19 0 0 0 0     
103 Latha 26 0 1 0 0 37WKS 37WKS 
104 Srrenidhi 21 0 0 0 0     
105 Devaki 24 0 0 0 0     
106 Santha 26 0 0 1 0     
107 Prema 21 0 0 0 0     
108 Anuradha 32 0 0 0 0   40WKS 
109 Kavitha 21 0 0 0 0     
110 Rukmani 25 0 0 0 0     
111 Revathy 24 0 0 0 0     
112 Rukmani 25 0 0 0 0     
113 Rekha 24 0 0 0 0     
114 Megala 27 0 0 0 0     
115 Selvi 23 0 0 0 0     
116 Viji 31 0 0 0 0 39WKS 39WKS 
117 Shanthi 22 0 0 0 0     
118 Lalitha 20 0 0 0 0     
119 Sasikala 38 0 0 0 0     
120 Jothi 30 0 0 0 0     
121 Sugam 20 0 1 0 0 38WKS 38WKS 
122 Selvi 20 0 0 0 0     
123 Bhavani 39 0 0 0 0     
124 Jaya 21 0 0 0 0     
125 Kokila 27 0 0 0 0     
126 Shanthi 20 0 1 0 0 37WKS 37WKS 
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S. 
No Name Age Parity BMI 
GA at sampling Previous H/o Preeclampsia 
Previous H/o Chronic Hypertension   BP 
127 Parveena 23 PRIMI 21.3 12WKS 110/80 
128 Amudha 28 G2P1L1 22.9 11WKS 110/70 
129 Kanmani 33 G2P1L1 21.3 11WKS 100/70 
130 Jeeva 21 G2P1L1 24.2 12WKS 100/70 
131 Sarala 32 PRIMI 30.5 12WKS 110/70 
132 Sheela 27 PRIMI 18 11WKS 110/80 
133 Sathya 23 PRIMI 22.9 12WKS 110/80 
134 Chitra 28 PRIMI 31.5 11WKS 110/80 
135 Jaya 26 G2P1L1 24 12WKS 110/80 
136 Shanthi 21 PRIMI 24.2 12WKS 110/80 
137 Fathima 27 G2P1L1 22.9 11WKS 110/80 
138 Tamil 19 PRIMI 21 12WKS 100/70 
139 Sabeena 30 PRIMI 24 11WKS 100/70 
140 Viji 26 G2P1L1 23 12WKS 100/80 
141 Prema 21 PRIMI 22 11WKS 100/80 
142 Lakshmi 26 G2P1L1 23 12WKS 100/80 
143 Zaibunisha 19 PRIMI 20 11WKS 120/80 
144 Manitha 21 PRIMI 25.9 12WKS 120/80 
145 Annkamu 25 G2P1L1 22 11WKS 120/80 
146 Shithya 26 G2P1L1 21 12WKS 110/80 
147 Sasikala 19 PRIMI 21 11WKS 120/80 
148 Nandhini 21 PRIMI 22 12WKS 110/80 
149 Priya 25 G2P1L1 23 11WKS 110/80 
150 Archana 26 G2P1L1 23 12WKS 120/80 
151 Thenmozhi 22 G4P1L1A2 22.5 11WKS 110/80 
152 Shanthi 21 PRIMI 20 12WKS 110/80 
153 Shyamala 21 PRIMI 21.5 11WKS 120/80 
154 Aameena 24 G2P1L1 22 12WKS 110/80 
155 Samundeewar 21 PRIMI 22 11WKS 110/80 
156 Mala 25 G2P1L1 22.5 12WKS 110/80 
157 Sudha 23 PRIMI 22 11WKS 120/80 
158 Renuka 20 PRIMI 21 12WKS 120/80 
159 Geetja 21 PRIMI 21 11WKS 110/80 
160 Chitra 20 PRIMI 21.5 12WKS 110/80 
161 Indrani 25 G2P1L1 22 11WKS 120/80 
162 Monika 26 PRIMI 22 12WKS 120/80 
163 Usha 30 G3P2L2 23.5 12WKS 120/80 
164 Lakshmi 24 PRIMI 23.5 11WKS 120/80 
165 Savithri 21 PRIMI 22 11WKS 120/80 
166 Sarala 20 PRIMI 21 12WKS 110/80 
167 Manimegalai 21 PRIMI 21.5 11WKS 110/80 
168 Devi 21 PRIMI 22 12WKS 110/80 
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S. 
No Name Age 
Previous H/o 
Preeclampsia 
Previous H/o 
Chronic Hypertension 
Previous 
H/o Gout 
Serum Uric 
Acid 
127 Parveena 23 0 0 0 4.9mg 
128 Amudha 28 0 0 0 3.8mg 
129 Kanmani 33 0 0 0 4.9mg 
130 Jeeva 21 0 0 0 4.0mg 
131 Sarala 32 0 0 0 4.3mg 
132 Sheela 27 0 0 0 5.0mg 
133 Sathya 23 0 0 0 3.8mg 
134 Chitra 28 0 0 0 5.5mg 
135 Jaya 26 0 0 0 3.2mg 
136 Shanthi 21 0 0 0 4.0mg 
137 Fathima 27 0 0 0 3.8mg 
138 Tamil 19 0 0 0 2.4mg 
139 Sabeena 30 0 0 0 2.9mg 
140 Viji 26 0 0 0 5.4mg 
141 Prema 21 0 0 0 5.6mg 
142 Lakshmi 26 0 0 0 6.8mg 
143 Zaibunisha 19 0 0 0 3.0mg 
144 Manitha 21 0 0 0 2.3mg 
145 Annkamu 25 0 0 0 3.7mg 
146 Shithya 26 0 0 0 2.0mg 
147 Sasikala 19 0 0 0 3.0mg 
148 Nandhini 21 0 0 0 2.1mg 
149 Priya 25 0 0 0 3.1mg 
150 Archana 26 0 0 0 3.7mg 
151 Thenmozhi 22 0 0 0 5.1mg 
152 Shanthi 21 0 0 0 4.5mg 
153 Shyamala 21 0 0 0 3.3mg 
154 Aameena 24 0 0 0 3.0mg 
155 Samundeewar 21 0 0 0 3.2mg 
156 Mala 25 0 0 0 4.0mg 
157 Sudha 23 0 0 0 2.4mg 
158 Renuka 20 0 0 0 6.0mg 
159 Geetja 21 0 0 0 5.4mg 
160 Chitra 20 0 0 0 3.5mg 
161 Indrani 25 0 0 0 3.2mg 
162 Monika 26 0 0 0 4.1mg 
163 Usha 30 0 0 0 2.9mg 
164 Lakshmi 24 0 0 0 2.9mg 
165 Savithri 21 0 0 0 2.4mg 
166 Sarala 20 0 0 0 3.2mg 
167 Manimegalai 21 0 0 0 3.1mg 
168 Devi 21 0 0 0 3.4mg 
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S. 
No Name Age Roll Over Test 
Urine 
Albumin RFT LFT 
Gestation 
Hypertension Preeclampsia 
127 Parveena 23   nil N N 0 0 
128 Amudha 28   nil N N 0 0 
129 Kanmani 33   nil N N 0 0 
130 Jeeva 21   nil N N 0 0 
131 Sarala 32   nil N N 0 0 
132 Sheela 27 positive 2+ N N 0 0 
133 Sathya 23   nil NN N 0 0 
134 Chitra 28   nil N N 0 0 
135 Jaya 26   nil N N 0 0 
136 Shanthi 21   nil N N 0 0 
137 Fathima 27   nil N N 0 0 
138 Tamil 19   nil N N 0 0 
139 Sabeena 30   nil N N 0 0 
140 Viji 26   nil N N 0 0 
141 Prema 21   nil N N 0 0 
142 Lakshmi 26 positive nil N N 1 0 
143 Zaibunisha 19   nil N N 0 0 
144 Manitha 21   nil N N 0 0 
145 Annkamu 25   nil N N 0 0 
146 Shithya 26   nil N N 0 0 
147 Sasikala 19   nil N N 0 0 
148 Nandhini 21   nil N N 0 0 
149 Priya 25   nil N N 0 0 
150 Archana 26   nil N N 0 0 
151 Thenmozhi 22   nil N N 0 0 
152 Shanthi 21   nil N N 0 0 
153 Shyamala 21   nil N N 0 0 
154 Aameena 24   nil N N 0 0 
155 Samundeewar 21   nil N N 0 0 
156 Mala 25   nil N N 0 0 
157 Sudha 23   nil N N 0 0 
158 Renuka 20   nil N N 0 0 
159 Geetja 21   nil N N 0 0 
160 Chitra 20   nil N N 0 0 
161 Indrani 25   nil N N 0 0 
162 Monika 26   nil N N 0 0 
163 Usha 30   nil N N 1 0 
164 Lakshmi 24   nil N N 0 0 
165 Savithri 21   nil N N 0 0 
166 Sarala 20   nil N N 0 0 
167 Manimegalai 21   nil N N 0 0 
168 Devi 21   nil N N 0 0 
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S. 
No Name Age 
HT+ 
Hyperurecemia HPU Preterm SGA 
GA at 
whichPreeclampsia is 
Detected  GA at Delivery 
127 Parveena 23 0 0 0 0     
128 Amudha 28 0 0 0 0     
129 Kanmani 33 0 0 0 0     
130 Jeeva 21 0 0 0 0     
131 Sarala 32 0 0 0 0     
132 Sheela 27 0 1 0 0 38WKS 38WKS 
133 Sathya 23 0 0 0 0     
134 Chitra 28 0 0 0 0     
135 Jaya 26 0 0 0 0     
136 Shanthi 21 0 0 0 0     
137 Fathima 27 0 0 0 0     
138 Tamil 19 0 0 0 0     
139 Sabeena 30 0 0 0 0     
140 Viji 26 0 0 0 0     
141 Prema 21 0 0 0 0     
142 Lakshmi 26 1 0 0 0   39WKS 
143 Zaibunisha 19 0 0 0 0     
144 Manitha 21 0 0 0 0     
145 Annkamu 25 0 0 0 0     
146 Shithya 26 0 0 0 0     
147 Sasikala 19 0 0 0 0     
148 Nandhini 21 0 0 0 0     
149 Priya 25 0 0 0 0     
150 Archana 26 0 0 0 0     
151 Thenmozhi 22 0 0 0 0     
152 Shanthi 21 0 0 0 0     
153 Shyamala 21 0 0 0 1     
154 Aameena 24 0 0 0 0     
155 Samundeewar 21 0 0 0 0     
156 Mala 25 0 0 0 0     
157 Sudha 23 0 0 0 1     
158 Renuka 20 0 0 0 0     
159 Geetja 21 0 0 0 0     
160 Chitra 20 0 0 0 0     
161 Indrani 25 0 0 0 0     
162 Monika 26 0 0 0 0     
163 Usha 30 0 0 1 0   39WKS 
164 Lakshmi 24 0 0 0 0     
165 Savithri 21 0 0 0 0     
166 Sarala 20 0 0 0 0     
167 Manimegalai 21 0 0 0 0     
168 Devi 21 0 0 0 0     
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S. 
No Name Age Parity BMI 
GA at sampling Previous H/o Preeclampsia 
Previous H/o Chronic Hypertension   BP 
169 Selvi 26 PRIMI 23 12WKS 110/80 
170 Thennarasi 24 PRIMI 22.5 10WKS 120/80 
171 Soniya 22 PRIMI 23.5 11WKS 110/80 
172 Sundari 20 PRIMI 21 12WKS 120/80 
173 Pushpa 21 PRIMI 22 12WKS 120/80 
174 Subhashini 24 G2P1L1 23.5 11WKS 120/80 
175 Dabreen 26 G2P1L1 23.5 12WKS 110/80 
176 Sivaranjani 22 PRIMI 23 12WKS 110/80 
177 Seetha 24 G2P1L1 23.5 12WKS 120/80 
178 Kavitha 22 PRIMI 22 12WKS 120/80 
179 Kalaiselvi 20 PRIMI 21.8 11WKS 120/80 
180 Manju 25 PRIMI 23.4 11WKS 110/80 
181 Priya 24 PRIMI 19.5 12WKS 120/80 
182 Meera 22 PRIMI 23.8 11WKS 120/80 
183 Yamuna 23 PRIMI 21.8 12WKS 120/80 
184 Govindammal 22 PRIMI 18.5 11WKS 110/80 
185 Saradha 22 PRIMI 20.5 10WKS 120/80 
186 Krishnaveni 22 PRIMI 21.4 12WKS 110/80 
187 Jeeva 24 G2P1L1 23.6 12WKS 110/80 
188 Sumitha 22 PRIMI 25.9 12WKS 110/80 
189 Shalini 23 PRIMI 22.9 12WKS 110/80 
190 Vinu 22 PRIMI 20 12WKS 120/80 
191 Priyanka 22 PRIMI 18.4 12WKS 120/80 
192 Keerthana 24 G2P1L1 24.2 11WKS 120/80 
193 Nithya 23 PRIMI 20 12WKS 120/80 
194 Vanaja 22 PRIMI 21 11WKS 110/80 
195 Gomathy 23 PRIMI 19.6 12WKS 110/80 
196 Roja 25 G2P1L1 20.2 11WKS 120/80 
197 Padmavathy 22 PRIMI 21 12WKS 110/80 
 
S. 
No Name Age 
Previous H/o 
Preeclampsia 
Previous H/o 
Chronic Hypertension 
Previous 
H/oGout Serum Uric Acid 
169 Selvi 26 0 0 0 3.2mg 
170 Thennarasi 24 0 0 0 3.6mg 
171 Soniya 22 0 0 0 3.2mg 
172 Sundari 20 0 0 0 2.8mg 
173 Pushpa 21 0 0 0 2.4mg 
174 Subhashini 24 0 0 0 2.2mg 
175 Dabreen 26 0 0 0 2.8mg 
176 Sivaranjani 22 0 0 0 4.0mg 
177 Seetha 24 0 0 0 3.5mg 
178 Kavitha 22 0 0 0 2.9mg 
179 Kalaiselvi 20 0 0 0 3.8mg 
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180 Manju 25 0 0 0 3.4mg 
181 Priya 24 0 0 0 3.2mg 
182 Meera 22 0 0 0 3.6mg 
183 Yamuna 23 0 0 0 3.2mg 
184 Govindammal 22 0 0 0 3.4mg 
185 Saradha 22 0 0 0 3.2mg 
186 Krishnaveni 22 0 0 0 3.1mg 
187 Jeeva 24 0 0 0 3.2mg 
188 Sumitha 22 0 0 0 3.0mg 
189 Shalini 23 0 0 0 3.2mg 
190 Vinu 22 0 0 0 3.4mg 
191 Priyanka 22 0 0 0 3.2mg 
192 Keerthana 24 0 0 0 3.5mg 
193 Nithya 23 0 0 0 2.9mg 
194 Vanaja 22 0 0 0 4.0mg 
195 Gomathy 23 0 0 0 3.7mg 
196 Roja 25 0 0 0 3.2mg 
197 Padmavathy 22 0 0 0 3.5mg 
 
S. 
No Name Age Roll Over Test 
Urine 
Albumin RFT LFT 
Gestation 
Hypertension Preeclampsia 
169 Selvi 26 positive nil N N 1 0 
170 Thennarasi 24   nil N N 0 0 
171 Soniya 22   nil N N 0 0 
172 Sundari 20   nil N N 0 0 
173 Pushpa 21   nil N N 0 0 
174 Subhashini 24   nil N N 0 0 
175 Dabreen 26   nil N N 0 0 
176 Sivaranjani 22   nil N N 0 0 
177 Seetha 24   nil N N 0 0 
178 Kavitha 22   nil N N 1 0 
179 Kalaiselvi 20   nil N N 0 0 
180 Manju 25   nil N N 0 0 
181 Priya 24   nil N N 0 0 
182 Meera 22 positive nil N N 1 0 
183 Yamuna 23   nil N N 0 0 
184 Govindammal 22   nil N N 0 0 
185 Saradha 22   nil N N 0 0 
186 Krishnaveni 22   nil N N 0 0 
187 Jeeva 24   nil N N 0 0 
188 Sumitha 22   nil N N 0 0 
189 Shalini 23 positive nil N N 1 0 
190 Vinu 22   nil N N 0 0 
191 Priyanka 22   nil N N 0 0 
192 Keerthana 24   nil N N 0 0 
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193 Nithya 23   nil N N 0 0 
194 Vanaja 22   nil N N 0 0 
195 Gomathy 23   nil N N 0 0 
196 Roja 25 positive nil N N 1 0 
197 Padmavathy 22   nil N N 0 0 
 
S. 
No Name Age 
HT+ 
Hyperurecemia HPU Preterm SGA 
GA at 
whichPreeclampsia 
is detected  GA at Delivery 
169 Selvi 26 0 0 0 0   39WKS3DAYS 
170 Thennarasi 24 0 0 0 0     
171 Soniya 22 0 0 0 0     
172 Sundari 20 0 0 0 0     
173 Pushpa 21 0 0 0 0     
174 Subhashini 24 0 0 0 1     
175 Dabreen 26 0 0 0 0     
176 Sivaranjani 22 0 0 0 0     
177 Seetha 24 0 0 0 0     
178 Kavitha 22 0 0 0 0     
179 Kalaiselvi 20 0 0 0 0     
180 Manju 25 0 0 0 0     
181 Priya 24 0 0 0 0     
182 Meera 22 0 0 0 0   39WKS 
183 Yamuna 23 0 0 0 0     
184 Govindammal 22 0 0 0 0     
185 Saradha 22 0 0 0 0     
186 Krishnaveni 22 0 0 0 0     
187 Jeeva 24 0 0 0 0     
188 Sumitha 22 0 0 0 0     
189 Shalini 23 0 0 0 0   40WKS 
190 Vinu 22 0 0 0 0     
191 Priyanka 22 0 0 0 0     
192 Keerthana 24 0 0 0 0     
193 Nithya 23 0 0 0 0     
194 Vanaja 22 0 0 0 0     
195 Gomathy 23 0 0 0 0     
196 Roja 25 0 0 0 0   40WKS 
197 Padmavathy 22 0 0 1 0     
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Key to Master Chart 
S. NO - Serial Number 
BMI   - Body Mass Index 
U/A  - Urine Albumin. 
HU  - Hypertension + Hyperuricemia 
HPU  - Hypertension + Proteinuria + Hyperuricemia 
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Proforma 
S. No 
Name 
Age 
Address 
Socioeconomic Status 
Phone Number 
Booking Status 
LMP 
EDD 
Menstrual History 
Obstetric History 
Previous H/o preeclampsia 
Previous H/o chronic hypertension 
Previous H/o gout 
Previous H/o diabetes 
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Family H/o 
Any H/o Bronchial Asthma / Throid / Cardiac Disorder / Renal Disorder / 
Epilepsy / Jaundice 
General examination 
Height 
Weight 
Anaemia 
Jaundice 
Pedal Edema 
Vitals 
PR 
BP 
RR 
Systemic Examination 
Respiratory System 
Cardiovascular System 
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CNS 
Obstetric Examination 
Investigation 
Urine Albumin 
Sugar Deposits 
VDRL 
NVP 
Blood Grouping & Typing 
CBC  
Blood Sugar 
Sr. Creatinine 
Serum Uric Acid 
USG Obstetrics 
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List of Abbreviations Used 
BMI    -  Body Mass Index 
Fig    -  Figure 
H/o    -  History of 
HT    -  Hypertension 
